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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 
Cancer targeted imaging plays an important role in cancer diagnosis. It allows us to 
rapidly evaluate tumor responses to certain treatments. Peptide-based imaging probes 
have been widely used in cancer targeted imaging (Aloj and Morelli, 2004; Okarvi, 2004; 
Reubi and Maecke, 2008). With the development of phage display technology, a great 
number of peptides have been identified specifically targeting to tumor cells in vitro and 
in vivo. However, due to peptides small size and relatively low binding affinity, it is 
difficult to identify the target of peptides. This thesis research is focused on: i). 
identifying the target of a specific peptide – HVGGSSV, which binds to radiation 
responsive tumors, by utilizing several affinity purification techniques especially phage 
display screening, and validating the target as a marker for evaluation of radiation 
treatment; ii). exploring the biological functions of the targeting protein. 
 
Tumor Targeted Imaging and Therapy 
 
Cancer is the uncontrolled growth of cells coupled with invasion and metastasis. It is a 
highly malignant disease. It is the leading cause of death worldwide. Despite the recent 
facts that cancer incidence and death rates for men and women in the United States 
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continue to decline, deaths from cancer worldwide are projected to continue rising, with 
an estimated 12 million deaths in 2030 (World Health Organization). Besides surgery, 
radiation therapy and chemotherapy are the mostly used methods to treat cancers. 
 
Radiation therapy 
Radiation therapy is the medical use of ionizing radiation as part of cancer treatment to 
control malignant cells. Radiation therapy may be used to treat localized solid tumors, 
such as cancers of the skin, tongue, larynx, brain, breast, lung, prostate or uterine cervix. 
It can also be used to treat leukemia and lymphoma. It works by damaging the DNA of 
cancerous cells through the use of one of two types of high energy radiation, photon or 
charged particle. This damage is either direct or indirect ionizing the atoms which make 
up the DNA chain. Indirect damage happens as a result of the ionization of water by high 
energy radiations, such as X-ray or gamma ray, forming free radicals, notably hydroxyl 
radicals, which then damage the DNA and form single- or double-stranded DNA breaks. 
Direct damage to DNA occurs through charged particles such as proton, boron, carbon or 
neon ions. Due to their relatively large mass, charged particles directly strike DNA and 
transfer high energy to DNA molecules and usually cause double-stranded DNA breaks. 
Tumor cells usually have impaired ability to repair DNA damage compared to normal 
cells. Therefore, the accumulating damages to cancer cells’ DNA cause them to die or 
proliferate more slowly. To minimize the damage to normal cells, the total dose of 
radiation therapy is usually fractionated into several smaller doses to allow normal cells 
time to recover. In clinics, to spare normal tissues from the treatment, shaped radiation 
beams are aimed from several angles of exposure to intersect at the tumor, providing a 
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much larger absorbed dose in the tumors than in the surrounding tissues. Brachytherapy, 
in which a radiation source is placed inside or next to the cancer area, is another 
technique to minimize exposure to healthy tissues during treatment of cancers in the 
breast, prostate and other organs. It is also common to combine radiotherapy with surgery, 
chemotherapy, hormone therapy or immunotherapy to maximize treatment efficiency. 
 
Chemotherapy 
Chemotherapy is the use of drugs to treat cancers throughout the body. Most 
chemotherapy drugs work by impairing mitosis, and killing actively dividing cancer cells. 
Based on their structure and the mechanism they use to attack cancer cells, the majority 
of chemotherapy drugs can be divided into the following classes (Oslo, 2010): 1). 
Alkylating agents, which are the oldest and most commonly used class of chemotherapy 
drugs. They work by attaching an alkyl group to DNA molecules and impairing cell 
functions. Some examples include: cisplatin, carboplatin and oxaliplatin (Scott, 1970). 2). 
Anti-metabolites. By imitating purines or pyrimidines, the anti-metabolic drugs become 
the building blocks of DNA or RNA. They prevent the real purines or pyrimidines from 
being incorporated into DNA during the “S” phase and stop the cell division. Some of the 
important drugs include: methotrexate, fludarabine and cytarabine (Peters et al., 2000). 3). 
Plant alkaloids. These alkaloids are derived from plants and block cell division by 
preventing microtubule function. The main examples are vinca alkaloids and taxanes 
(Takimoto CH, 2008). 4). Topoisomerase inhibitors. Inhibition of type I or type II 
topoisomerases interferes with proper DNA unwinding and blocks both transcription and 
replication of DNA. Some mostly used examples include camptothecin and etoposide 
 4
(Takimoto CH, 2008; Wall et al., 1966). 5). Anthracycline. This class of drugs can 
intercalate between base pairs of DNA/RNA and prevent the replication of rapidly 
growing cancer cells. The first anthracycline discovered was daunorubicin, which was 
produced naturally by Streptomyces bacteria. Doxorubicin was developed shortly after, 
and many other related compounds have followed (Weiss, 1992). 
 
Targeted therapy 
In recent years, with increased understanding of cancer biology and signaling networks, 
newer chemotherapy agents that do not directly interfere with DNA were developed to 
target specifically to cancer cells. One major target is the tyrosine kinase. Tyrosine 
kinases play key roles in cell proliferation, differentiation, migration and apoptosis in 
response to external and internal stimuli (Schlessinger, 2000). Recent advances have 
implicated the role of tyrosine kinases in tumor development and progression. They may 
acquire transforming functions due to mutation(s) or overexpression (Blume-Jensen and 
Hunter, 2001). For examples, somatic mutations in the EGFR have been associated with 
human bladder and cervical cancers. Point mutations in FGFR that results in abnormal 
receptor dimerization and activation were identified in multiple myeloma (Zwick et al., 
2002). The aberrant fusion of tyrosine kinase c-ABL with its partner protein BCR causes 
the kinase hyperactivation found in Chronic myelogenous leukemia (Ben-Neriah et al., 
1986; Daley et al., 1990; Goga et al., 1995). Overexpression of wild type or mutated 
forms of EGFR is documented in 40% of cases of glioblastoma multiforme (Wong et al., 
1987) and 40%-50 % of bladder cancer patient (Smith et al., 1989). The constitutive 
oncogenic activation of tyrosine kinases can be blocked by specific tyrosine kinase 
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inhibitors. Most small molecular inhibitors generated so far have been ATP mimics. They 
compete with ATP for binding to tyrosine kinases and inhibit their functions (Davies et 
al., 2000; Gazit et al., 1989). The most successful examples are Gleevec, Iressa and 
Tarceva. The extracellular domain of the receptor tyrosine kinase provides an excellent 
target for monoclonal antibodies. The revolution in antibody technology now allows us to 
produce humanized, chimeric or bispecific antibody for targeted cancer therapy 
(Bennasroune et al., 2004; Houshmand and Zlotnik, 2003). Several McAbs have already 
been approved by the FDA, which include Cetuximab and Panitumumab targeted to 
EGFR/Erbb1; and Traztuzumab and Pertuzumab targeted to Her2/Erbb2 in breast cancer. 
Bevacizumab (Avastin) is another McAb that blocks VEGF-A and VEGFR interaction 
and was the first clinically available angiogenesis inhibitor to treat colon, lung and breast 
cancers. The targeted therapies are less harmful to normal cells and greatly increased the 
efficacy of cancer treatments. 
 
Evaluation of cancer treatment efficacy 
However, different types of cancers possess different mutations. Even cancers of the 
same type show different growth characteristics at different locations and in different 
patients. The heterogeneity of cancers underlies their variable responses to the same 
treatment. Currently, cancer response is measured by imaging assessment of tumor 
volumes or by repeated biopsy to analyze tumor pharmacodynamics. Those processes are 
time consuming and inefficient. Speed and accuracy in detecting a cancer’s response to 
treatment is critical for successfully combating it. Therefore, new technologies are 
needed for doctors to decide almost immediately whether a chosen treatment is working 
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or not for one patient. Recently, advances in phage display-related technologies have 
facilitated the use of small peptide derivatives as probes for recognition and targeting 
tumors. We employed this technique and identified several peptides that specifically 
homed to radiation or drug treatment responsive tumors (Han et al., 2008; Passarella et al., 
2009). After being conjugated to optically active imaging agents, those peptides can be 
used to rapidly assess the pharmacodynamic response of cancer to treatments. In this 
thesis work, by using several molecular biological techniques, I identified the receptor of 
one of those peptides (HVGGSSV peptide) and explored its functions in the cell.  
 
Principle of phage display  
A phage is a type of virus that infects bacteria. Typically, phage consist of an outer 
protein capsid enclosing genetic material and a tail (Fig. 1A). Due to their simple 
structure, phage have been developed into a powerful tool in biological studies. Phage 
display was originally invented by George P. Smith in 1985, and he demonstrated the 
display of exogenous peptides on the surface of filamentous phage by fusing the DNA of 
the peptide on to the capsid gene of filamentous phages (Smith, 1985) (Fig. 1B). This 
technology was further developed and improved to display large proteins such as 
enzymes and antibodies (Fernandez-Gacio et al., 2003; McCafferty et al., 1990). The 
connection between genotype and phenotype enables large libraries of peptides or 
proteins to be screened in a relatively fast and economic way. The most common phage 
used in phage display are the M13 filamentous phage and the T7 phage (Krumpe et al., 
2006; Smith and Petrenko, 1997). 
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The principle of phage display is based on affinity purification. First, DNAs encoding the 
proteins or peptides of interest are ligated into certain phage coat proteins genes to create 
a phage library. Then the phage library is mixed with a relevant target. By immobilizing 
the target to the surface of a well or beads, a phage that displays a protein or peptide that 
binds to the target on its surface will remain while others are removed by washing. Those 
that remain can be eluted, used to produce more phage (by bacterial infection) and so 
produce a phage mixture that is enriched with the binding phage. The repeated cycling of 
these steps is referred to as 'panning', in reference to the enrichment of a sample of gold 
by removing undesirable materials. The DNAs within phage eluted in the final step are 
collected and sequenced to identify the interacting proteins or protein fragments. 
Figure 1: Phage Structure and the principle of using phage to display 
foreign peptide on phage surface 
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Application of phage display 
The applications of phage display technology include determination of binding partners 
of proteins, peptides or DNAs (Gommans et al., 2005). The technique is also used to 
study enzyme evolution in vitro for engineering biocatalysts (Pedersen et al., 1998). 
Phage display is also a widely used method in drug discovery. It can be used for finding 
new ligands, such as enzyme inhibitors, receptor agonists and antagonists, to target 
proteins (Pasqualini et al., 1995; Perea et al., 2004; Ruoslahti, 1996; Su et al., 2005). 
Invention of antibody phage display revolutionized drug discovery (McCafferty et al., 
1990). Millions of different single chain antibodies on phages are used for isolating 
highly specific therapeutic antibody leads. One of the most successful examples was 
adalimumab (Abbott Laboratories), the first fully human antibody targeted to TNF alpha 
(Lorenz, 2002).  
 
In vivo phage display 
Because isolating or producing recombinant membrane proteins for use as target 
molecules in phage library screening often faced insurmountable obstacles, innovative 
selection strategies such as panning against whole cells or tissues were devised (Molek et 
al., 2011). Since cells inside the body may express different surface markers and possess 
different characteristics from cells cultured in vitro, in vivo phage bio-panning was 
developed to identify more physiologically relevant biomarkers (Pasqualini and Ruoslahti, 
1996). Since its invention, in vivo phage display has been extensively used to screen for 
novel targets for tumor therapy. The majority of those studies focused on analyzing the 
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structure and molecular diversity of tumor vasculature and selecting tumor stage- and 
type-specific markers on tumor blood vessels (Arap et al., 2002a; Arap et al., 2002b; 
Rajotte et al., 1998; Sugahara et al., 2010; Valadon et al., 2006). Recently, the use of this 
technique was expanded to the discovery of new cancer biomarkers to evaluate treatment 
efficacy. In this research, the authors first treated tumors in mice with either radiation or 
tyrosine kinase inhibitors. Then a peptide phage library was injected via the tail vein to 
determine and measure tumor binding. After several rounds of screening and enrichment 
of phage isolated from the treated tumors (Fig. 2), two phage clones were identified, 
encoding HVGGSSV or GIRLRG peptides. Both peptides tend to target to treatment 
responsive tumors. These binding was further confirmed by fluorescent labeling and 
imaging (Han et al., 2008; Passarella et al., 2009). 
 
Peptides as probes for tumor targeted imaging 
Antibodies, especially monoclonal antibodies, have been successfully utilized as cancer 
therapeutic and diagnostic agents due to their high target specificity and affinity. 
However, due to the large size of antibody (150kDa) and limited target permeability, 
non-specific uptake into the reticuloendothelial system, and immunogenicity, most 
antibody-based therapeutics are of limited efficacy (Lin et al., 2005; Stern and Herrmann, 
2005). In contrast to antibodies, peptides are much smaller molecules (1-2 kDa). Peptides 
have favorable biodistribution profiles compared to antibodies, as they are characterized 
by high uptake in the tumor tissue and rapid clearance from the blood. In addition, 
peptides have increased 
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capillary permeability, allowing more efficient penetration into tumor tissues. Also 
peptides are easy to make and safe to use, they will not elicit an immune response 
(Ladner et al., 2004). With all these advantages, peptides have been increasingly 
considered as a good tumor targeted imaging probes (Aloj and Morelli, 2004; Okarvi, 
2004; Reubi and Maecke, 2008). To date, a large number of peptides targeting tumor 
receptors have already been successfully identified and characterized for tumor imaging, 
such as integrin (RGD), somatostatin, gastrin-releasing peptide, cholecystokinin, 
Figure 2: The processes of in vivo phage display, for screening peptides that 
specifically target to radiation or drug treated tumors. 
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glucagon-like peptides-1 and neuropeptide-Y (Cai et al., 2008; Hallahan et al., 2003; 
Korner et al., 2007; Miao and Quinn, 2007; Reubi, 2003; Reubi, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
For use as in vivo imaging probes, peptides can be directly or indirectly labeled with a 
wide range of imaging moieties according to the imaging modality. For instance, near-
infrared (NIR) fluorescent dyes or quantum dots have been labeled for optical imaging 
(Fig. 3), several radionuclides have been employed for positron emission tomography 
(PET) or single-photon emission computed tomography (SPECT), and paramagnetic 
agents have been used for magnetic resonance imaging (MRI) (Frangioni, 2003; Reubi 
and Maecke, 2008). Peptides can also be conjugated to other tumor targeted polymers or 
nanoparticles and dramatically increase their tumor targeted selectivity and efficiency 
(Hariri et al., 2010a; Hariri et al., 2010b; Lowery et al., 2010; Passarella et al., 2010). 
Figure 3. HVGGSSV peptide labeled with near-infrared (NIR) fluorescent dyes 
specifically located to irradiation treated tumors. a). brain tumor (D54 human 
glioblastoma cell), b). lung tumor (H460 cell), c) colon cancer liver metastasis (HT22 
cell), d). prostate cancer subcutaneous model (PC-3 cell), e). breast cancer subcutaneous 
model (MDA-MB-231 cell). (Adapted from Han et al., 2008).  
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Peptide receptor identification 
Peptide-based probes have great potential in clinical cancer diagnostics and treatment. To 
understand the physiology underlying peptide binding, we need to identify its molecular 
targets. However, peptides are usually unstable. Their surface charges and structures are 
dramatically altered environmental conditions. In addition, their small size confers low 
binding affinity. Therefore, traditional affinity purification methods are of little use due to 
extensive non-specific binding. To date, there are very few identified receptors for 
peptides in contrast to the great number of discovered cancer targeting peptides (Teesalu 
et al., 2009). New strategies are needed for identifying a peptide’s receptors. In our recent 
studies of one peptide (HVGGSSV), we utilized a phage cDNA library screening to 
search for the peptide’s receptors. Because several rounds of phage display screening can 
significantly enrich the low-affinity or low-abundance proteins, we successfully 
identified a PDZ protein - TIP-1 as the target of HVGGSSV peptide (Wang et al., 2010). 
This result demonstrated the potential of screening phage-displayed cDNA library in the 
discovery of molecular targets of the peptides with simple structure and low affinity. 
 
PDZ Proteins and Rho GTPases 
 
PDZ domain structure 
The PDZ domain is a very common structural domain involved in protein-protein 
interactions. In the mouse genome, for example, 928 PDZ domains have been recognized 
in 328 proteins (Spaller, 2006). It is a highly evolutionally conserved domain and can be 
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found in bacteria, yeast, plants, and animals (Ponting, 1997). The name ‘PDZ’ is an 
acronym combining the first letters of three proteins – post synaptic density proteins 
(PSD95), Drosophila disc large tumor suppressor (DlgA), and zonula occludens-1 protein 
(ZO-1) – which were the first three proteins discovered to share the domain. PDZ 
domains usually consists of 80-90 amino acids forming two alpha-helices and six beta-
strands structure. The groove formed between the alpha2-helix and the beta6-strand can 
accommodate the peptide from its interacting proteins (Fig. 4A).  
 
PDZ domain binding specificity 
Most PDZ domains recognize short amino acid motifs at the C-termini of target proteins. 
Based on their recognized amino acid patterns, PDZ domains are classified into three 
major classes: (1) class I domains, which recognize the motif S/T-X-I/L/V; (2) class II 
domains, which recognize the motif Φ-X-Φ; and (3) class III domains, which recognize 
the motif D/E-X- Φ, where Φ represents a hydrophobic residue. Although the last three 
amino acids on the PDZ ligands play critical roles in PDZ domain binding, a recent large-
scale specificity map of the PDZ domain family revealed that the family is surprisingly 
complex and diverse, recognizing up to seven C-terminal ligand residues and forming at 
least 16 unique specificity classes across human and worm (Tonikian et al., 2007; 
Tonikian et al., 2008). Some PDZ domains can also bind to internal sequences of target 
proteins. The most well-characterized example of this nature is the interaction between 
the PDZ domain of the syntrophin (or PSD-95) protein with the internal beta-hairpin 
finger structure of the nNOS protein (Brenman et al., 1996; Hillier et al., 1999). Besides 
interacting with peptide structures on proteins, several PDZ domains were shown to bind 
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to lipid molecules. The best example is the second PDZ domain of Par-3 which binds to 
phosphoinositides (PIPs). This interaction was shown to be critical for epithelial cell 
polarization (Wu et al., 2007a). 
Although most PDZ domains exist as monomers, some can form dimers (Im et al., 2003a; 
Im et al., 2003b; Utepbergenov et al., 2006). For example, the second PDZ domain of the 
ZO1 protein forms a dimer by extensive symmetrical domain swapping of beta-strands. 
The formation of the PDZ dimer does not affect the binding to its target proteins because 
the peptide-binding sites of both PDZ domains remain open. Therefore, dimerization of 
ZO1 provides a structural basis for the polymerization of the tight junction proteins – 
claudins (Wu et al., 2007b). 
 
Biological functions of PDZ proteins 
PDZ proteins usually contain multiple PDZ domains or other functional domains (Fig. 
4B). This structural feature enables them to function as scaffold proteins and assemble 
large intracellular complexes to mediate diverse cellular functions. PDZ proteins are 
often found at specialized subcellular locations, such as epithelial junctions (Niessen, 
2007), neuronal postsynaptic densities (Kim and Sheng, 2004), and immunological 
synapses of T cells (Ludford-Menting et al., 2005). The various locations of PDZ proteins 
inside the cell indicate the diverse functions of PDZ domains. For examples, the tight 
junctional scaffolding molecules ZO-1 and ZO-2 are PDZ domain containing proteins. 
These proteins interact directly with other proteins - occludin, claudins and JAMs via 
their PDZ domains, and cluster these proteins at tight junctions. The C-terminus of ZO-1 
and ZO-2 can associate with actin, thus providing a direct link with the cytoskeleton and 
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stabilizing tight junctions (Umeda et al., 2006). In the establishment and maintenance of 
apical-basal cell polarity, three groups of proteins play a central role: The Crumbs-Pals1-
Patj and the Par3-Par6-aPKC protein complexes localize to the apical membrane and 
promote apical-membrane-domain identity (Margolis and Borg, 2005; Suzuki and Ohno, 
2006). Their function is antagonized by the basolaterally localized Lgl-Scrib-Dlg protein 
complexes, which together promote basolateral membrane identity (Bilder, 2004). 
Among these nine proteins, six of them contain PDZ domains (Pals1, Patj, Par3, Par6, 
Scrib and Dlg). In the nervous system, membrane associated PDZ proteins such as PSD-
95 and GRIP organize glutamate receptors (NMDAR, AMPAR) and their associated 
signalling proteins and determine the size and strength of synapses (Gramates and Budnik, 
1999; Im et al., 2003b; Mori et al., 1998). Furthermore, PDZ proteins on the surface of 
cargo vesicles can bind to specific kinesins and myosins (molecular motors) and regulate 
protein transportation. For instance, the PDZ domains of PSD-95, SAP97 and S-SCAM 
interact directly with the C terminus of KIF1B (kinesin family member 1B), a kinesin 
motor (Mok et al., 2002). SAP97 can also bind, through its GK (guanylate kinase-like) 
domain, to KIF13B/GAKIN (kinesin family member 13B) (Asaba et al., 2003), and 
through its N-terminal L27 domain to myosin-VI (Wu et al., 2002). 
 
Regulation of PDZ-mediated interactions 
As the PDZ domain is one of the major signaling modules inside the cell, its interactions 
need to be finely regulated. Just like the function regulation of other domains, 
phosphorylation of Ser, Thr or Tyr within the PDZ ligand plays a major role in 
modulating PDZ-mediated interactions. For example, the interaction between the NR2B  
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subunit of the NMDA receptor with PSD-95 is negatively regulated by phosphorylation 
on the Ser residue (LSSIESDVCOOH ) by CK2, which eventually decreases the surface 
expression of NR2B in neurons (Chung et al., 2004). Besides phosphorylation of the ‘-2’ 
site within the PDZ ligand, other positions in the ligand can also be phosphorylated. The 
Ser residue at ‘-5’ site in the C-terminal PDZ ligand (ERKLSSESQVCOOH) of LRP4 is 
phosphorylated by CaMKII which disrupts the interaction with PSD-95 and SAP97 (Tian 
et al., 2006). Although many studies have reported that phosphorylation at the C-terminus 
of proteins negatively modulates PDZ interactions, others have shown that 
phosphorylation does not affect or even promotes PDZ interactions (Adey et al., 2000; 
Chen et al., 2006). Several studies have also reported that phosphorylation on the PDZ 
A B
Figure 4: A). Representative structure of a PDZ domain (green) binding with a 
peptide (red). B). PDZ proteins often contain multiple PDZ domains and other 
structural domains. (Adapted from Kim and Sheng, 2004). 
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domain itself may also disrupt PDZ protein-protein interactions. For example, the 
activation of the NMDA receptor induces a CaMKII-dependent phosphorylation of SAP-
97 or PSD-95. The phosphorylation sites are located in the alpha2-helix structure, which 
is the binding site of the PDZ domain. Therefore, phosphorylation causes the dissociation 
of NR2A from PSD-95 or SAP-97 and negatively regulates spine growth and synaptic 
plasticity (Mauceri et al., 2007; Steiner et al., 2008). 
Although phosphorylation is important in regulating PDZ protein-protein interactions, 
intramolecular disulfide bond formation in PDZ domains can also modulate PDZ ligands 
binding. For example, the PDZ5 doamin of InaD, a PDZ scaffold protein in photoreceptor 
cells that can undergo a light-dependent conformational change, exists in a redox-
dependent equilibrium between two conformations: the reduced form, which can bind 
PDZ ligands, and the oxided form, in which the ligand binding site is distorted due to the 
formation of a strong intramolecular disulfide bond (Mishra et al., 2007).  
Some PDZ domain containing proteins also have a PDZ-binding motif at their C-terminal 
tail. The binding site of the PDZ domain in these proteins can be occupied by their own 
C-terminal sequences, thereby inhibiting the binding of other PDZ ligands. This 
structural feature is found in the proteins NHERF-1, PDZK1, X11α and Tamalin. The 
autoinhibition of PDZ domain functions can be counteracted by phosphorylation of the 
C-terminal sequence or the association of other PDZ proteins with the C-terminal tails 
(Cheng et al., 2009; LaLonde and Bretscher, 2009; Li et al., 2007; Long et al., 2005; 
Morales et al., 2007; Sugi et al., 2007). 
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PDZ proteins in carcinogenesis 
PDZ proteins are involved in many cell signaling pathways. They are crucial for 
maintaining normal cellular functions. Disruption of PDZ interactions will lead to 
diseases (Montell, 2000; Obenauer et al., 2006; Rogelj et al., 2006), especially cancers. 
Recent evidence indicate that loss of cell polarity is a hallmark of cancer, and is 
correlated with more aggressive and invasive cancers (Thiery, 2002). Basic mechanisms 
of cell polarity are often targeted by oncogenic effectors. Several crucial cell-polarity 
proteins, which contain PDZ domains, are known targets of oncoproteins. For example, 
the E6 proteins from high-risk human papillomavirus are characterized by the presence of 
a PDZ binding motif in their C-terminus, through which they bind and degrade a number 
of PDZ proteins, including MAGI-1, Dlg, Scrib and Par-3. Degradation of these proteins 
disrupts cell junction integrity, promotes epithelial-to-mesenchymal transition, and 
eventually leads to cervical cancers (Kranjec and Banks, 2010; Tomaic et al., 2009). On 
the other hand, deletion of the PDZ binding motif on E6 prevents its immortalization 
effects (Spanos et al., 2008). Similarly, the oncogenic potential of several other 
oncoproteins, such as E4-ORF1 and Tax1, also depends on their ability to inactivate key 
cell polarity PDZ proteins (Frese et al., 2003; Hall and Fujii, 2005; Javier, 2008). 
Although many PDZ proteins function as tumor suppressors, some can promote tumor 
formation. For example, overexpression of the PDZ protein, Dishevelled, activates Wnt 
signaling and contributes to the pathogenesis of mesothelioma (Uematsu et al., 2003). 
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Rho-family GTPases 
The ability of cells to move around depends upon the reorganization of the actin 
cytoskeleton, which includes generating protrusions at the leading edge and contraction 
in the body of the cell. Protrusion and contraction require different types of actin filament 
arrays: protrusion of the lamellipodia requires rapidly growing, branched filament arrays, 
whereas contractility requires myosin-rich, parallel bundles of actin filaments called 
stress fibers. Thus, an accurate system is needed for the cell to construct distinct actin-
based structures in different sub-cellular sites simultaneously and then constantly remodel 
those structures as the cell moves forward. In 1992, a pair of landmark papers from Anne 
Ridley, Alan Hall and co-workers were published and established roles for the small 
guanine nucleoside triphosphatases (GTPases) in the generation of stress fibers and 
lamellipodia (Ridley and Hall, 1992; Ridley et al., 1992). Since then, over 20 Rho-family 
GTPases have been discovered (Boureux et al., 2007). 
 
Rho GTPases functions  
Rho GTPases are small (~21kDa) signaling G proteins and are highly conserved from 
lower eukaryotes to plants and mammals. They form a distinct family within the Ras-like 
protein superfamily, which also includes the Ras, Rab, Arf and Ran families. Rho 
GTPases differ from other Ras superfamily members by the presence of a Rho-specific 
insert domain.  
Most Rho GTPase family members act as molecular switches, cycling between a GTP-
bound active form and a GDP-bound inactive form (Jaffe and Hall, 2005). Once activated, 
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Rho GTPases bind different effector molecules and trigger different signaling cascades to 
direct cellular responses. Rho GTPases have been implicated in many cellular processes 
including actin and microtubule cytoskeleton organization, motility, cell adhesion, cell 
division, vesicle trafficking, phagocytosis and transcriptional regulation (Jaffe and Hall, 
2005). Rho GTPases can be divided into 8 different subfamilies, which include the most 
studied Rac, Cdc and Rho families (Boureux et al., 2007). The activation of RhoA, Rac1 
or Cdc42 leads to the assembly of contractile actin-myosin filaments, protrusive actin-
rich lamellipodia, and protrusive actin-rich filapodia, respectively (Etienne-Manneville 
and Hall, 2002). Rac1 and Cdc42 initiate peripheral actin polymerization through 
recruiting the WASP/WAVE and Arp2/3 complex. Arp2 and Arp3 closely resemble the 
structure of monomeric actin and serve as nucleation sites for new actin filaments. 
Branched actin networks are created as a result of this nucleation of new filaments 
(Suetsugu et al., 2002). On the other hand, RhoA stimulates actin polymerization through 
the diaphanous-related formin (DRF) and mDial. mDial directly binds to the barbed end 
of an actin filament and initiates actin polymerization (Zigmond, 2004). In addition to 
elongation, RhoA can also promote phosphorylation of myosin light chain (MLC) 
through one of its downstream effectors – Rho-associated protein kinase (ROCK). This in 
turn leads to the activation of myosin II and promotes the actin filament cross-linking 
(Riento and Ridley, 2003). Rho GTPases can also regulate microtubule dynamics. For 
example, Cdc42/Rac1 dependent activation of PAK can phosphorylate Op18/stathmin 
and inhibit its microtubule plus ends disassembly activity (Cassimeris, 2002; Daub et al., 
2001). Through IQGAP, a Rac1/Cdc42 effector, Cdc42/Rac1 can also recruit microtubule 
plus end binding protein – CLIP-170 to the leading edge of migrating cells, and promote 
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plus end capture (Fukata et al., 2002a). The effect of RhoA on microtubule dynamics is 
likely to be context dependent. In neurons, RhoA promote the collapse of microtubules 
through inactivation of CRMP-2, a microtubule assembly protein, by ROCK 
phosphorylation (Fukata et al., 2002b). In migrating fibroblasts, on the other hand, RhoA 
promotes the formation of stabilized microtubules. It is not clear how stabilization occurs, 
although it appears to be mediated by mDia (Palazzo et al., 2001). 
In addition to their cytoskeletal effects, Rho GTPases also regulate several signaling 
pathways. Rho, Rac, and Cdc42 are capable of activating the JNK and p38 MAP kinase 
pathway, although this is dependent on cell context (Coso et al., 1995; Minden et al., 
1995). RhoA, Rac1 and Cdc42 have been reported to activate NFκB in response to a 
variety of stimuli (Perona et al., 1997). For example, Rac1 and Cdc42 can stimulate the 
production of reactive oxygen species (ROS) and inflammatory cytokines, both of which 
are potent activators of NFκB (Bromberg et al., 1994; Joneson and Bar-Sagi, 1998; 
Pulecio et al., 2010; Qian et al., 2003; Tapon et al., 1998). 
 
Regulation of Rho GTPases functions 
The activation of Rho GTPases is mediated by specific guanine nucleotide exchange 
factors (GEFs), which promote the release of bound GDP and subsequent binding of the 
GTP (Fig.5). In their active state, Rho GTPases interact with their downstream effectors 
to modulate their activity and location. The signal is terminated by hydrolysis of GTP to 
GDP, a reaction that is stimulated by GTPase activating proteins (GAPs) (Bos et al., 
2007). Rho proteins are also frequently post-translationally modified at their C-terminal 
CAAX (where C represents cysteine, A is an aliphatic amino acid, and X is a terminal 
 22
amino acid) tetrapeptide motifs with the addition of a lipidic group by prenylation or 
palmitoylation. This modification promotes proper subcellular localization of Rho 
GTPases to the plasma membrane and/or endomembranes, which is required for their 
biological activity (Adamson et al., 1992; Roberts et al., 2008). In addition, guanine 
nucleotide dissociation inhibitors (GDIs) negatively regulate the activity of Rho GTPases 
by binding to the C-terminal prenyl group, blocking the release of GDP form Rho 
GTPases, preventing their membrane association and sequestering them in the cytoplasm, 
and thus inhibiting their access to downstream targets (Dovas and Couchman, 2005). Rho 
GDIs can bind to either the GTP- or the GDP-loaded forms. 
GEF activity requires a conserved domain known as the Dbl homology (DH) domain for 
Rho GTPases binding. Meanwhile, almost all GEFs contain a pleckstrin homology (PH) 
domain adjacent and C-terminal to the DH domain. These two domains provide the 
minimal structural unit that is required to catalyze the GTP/GDP exchange reaction in 
vivo. PH domains assist the exchange reaction and in some cases participate in binding to 
the GTPases, but they can also bind to phospholipids and to other proteins (Rossman et 
al., 2005; Schmidt and Hall, 2002). To date, more than 70 RhoGEFs, 60 RhoGAPs and 3 
RhoGDIs have been identified in mammals. They outnumber their target GTPases by a 
factor of three, which reflects the complexity of the regulation of Rho GTPases (Rossman 
et al., 2005).  
In recent years, several interactions between RhoGEFs and scaffold proteins containing 
PDZ domains have been reported (Audebert et al., 2004; Liu and Horowitz, 2006; Park et 
al., 2003; Penzes et al., 2001; Radziwill et al., 2003). These PDZ scaffold proteins 
promote the formation of multiprotein signaling complexes with RhoGEFs. They can  
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target the RhoGEFs to specific locations in the cell, and spatially and temporally restrict 
their nucleotide exchange activity and subsequent GTPases activation. A recent 
bioinformatics analysis revealed that more than 40% of RhoGEFs contain a putative PDZ 
binding motif at the C-terminus (Garcia-Mata and Burridge, 2007), which further 
 
Figure 5: Regulation of the activities of Rho GTPases. GEFs activate Rho GTPases 
by promoting the exchange of GDP for GTP. Active Rho GTPases are associated with 
the plasma membrane and bind different effector proteins to trigger different 
downstream signaling pathways. The low intrinsic GTP hydrolysis activity of Rho 
GTPases is enhanced by the binding of GAPs, resulting in an inactive GDP-bound 
GTPase and the shutdown of signaling. GDIs sequester Rho GTPases in the cytosol and 
inhibit their functions (Iden and Collard, 2008).
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suggested that the interaction between RhoGEFs and PDZ proteins is a general 
mechanism that controls RhoGEFs targeting and activation. 
Rho GTPases in cancer development 
As well as contributing to physiological processes, Rho GTPases have been found to 
contribute to pathological processes including cancer. Rho GTPases have been reported 
to contribute to most steps of cancer initiation and progression. Unlike the closely related 
Ras oncoprotein, which often contains mutations that result in constitutively activation, 
Rho GTPases are found only rarely mutated in tumors, whereas their expression and/or 
activity are frequently altered. For example, several Rho GTPases are upregulated in 
some human tumors, including RhoA, RhoC, Rac1, Rac2, Rac3, Cdc42, Wrch2/RhoV 
and RhoF (Gomez del Pulgar et al., 2005; Gouw et al., 2005). 
RhoA has been implicated in virtually all stages of cancer progression. Constitutively 
active RhoA can stimulate transformation in vitro (Jaffe and Hall, 2005). RhoA activity is 
important for collective cell invasion (Gaggioli et al., 2007). RhoA can also regulate the 
production and secretion of MMPs, affecting matrix remodeling and tumor cell invasion 
(Lozano et al., 2003). Some reports indicate that RhoA and its downstream target ROCK 
are needed for cancer cell extravasation (Miles et al., 2008).  
Rac1 is over-expressed in various tumors and accumulating evidence indicates that Rac1 
dependent signaling is important for malignant transformation (Gomez del Pulgar et al., 
2005). Rac1 is one of the few Rho GTPases mutated in some tumors (Hwang et al., 2004). 
A splice variant of Rac1, Rac1b, was found upregulated in colon cancers (Jordan et al., 
1999). It does not bind RhoGDIs and thus is predominantly present in the GTP-bound 
state. It stimulates cell survival and cell cycle progression through NFκB (Matos and 
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Jordan, 2006; Singh et al., 2004; Visvikis et al., 2008). Rac1 can contribute to cancer cell 
proliferation via regulation of the cell cycle: for example, it stimulates expression of 
cyclin D1 and induces cell transformation in vitro (Benitah et al., 2004; Jaffe and Hall, 
2005). Rac1 can also contribute to cancer cell invasion by regulating the production of 
MMPs and their inhibitors, the tissue-specific inhibitors of MMP (TIMPs) (Lozano et al., 
2003). 
Cdc42 expression is upregulated in some breast cancers (Fritz et al., 1999), however, 
liver-specific knockout indicates that loss of Cdc42 enhances liver cancer development 
(van Hengel et al., 2008), suggesting that the contribution of Cdc42 to cancer progression 
may be tissue-specific. By regulating trafficking of receptors and preventing their 
degradation, Cdc42 can stimulate transformation and contribute to Ras-induced 
transformation as well (Jaffe and Hall, 2005; Wu et al., 2003). Cdc42 can also affect cell 
cycle progression by regulating chromosome segregation during mitosis. Cdc42 
knockdown was found to induce chromosome misalignment during cell division, leading 
to multinucleated cells (Yasuda et al., 2006). 
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CHAPTER II 
 
TIP-1 TRANSLOCATION ONTO THE CELL SURFACE IS A MOLECULAR 
BIOMARKER OF TUMOR RESPONSE TO IONIZING RADIATION 
 
Abstract 
 
Even though anatomic and functional imaging have been extensively investigated and 
applied to assess tumor response to treatment, new biomarkers with sound biological 
relevance are still needed to assess tumor response to treatment in a time-efficient manner. 
We have previously shown in vivo that a small peptide (HVGGSSV) demonstrated the 
potential as a molecular imaging probe to distinguish tumors responding to ionizing 
radiation (IR) and/or tyrosine kinase inhibitor treatment from those of non-responding 
tumors. In this study we have identified Tax interacting protein 1 (TIP-1, also known as 
Tax1BP3) as a molecular target that enables selective binding of the HVGGSSV peptide 
within irradiated xenograph tumors. The peptide binding within irradiated tumors was 
blocked by a TIP-1 specific antibody as demonstrated by optical imaging of tumors and 
via immunohistochemical staining of the tumor tissues.  Intracellular TIP-1 relocated to 
the plasma membrane surface within the first few hours after exposure to IR and before 
the onset of treatment associated apoptosis and cell death, suggesting a potential 
mechanism to assess tumor response to IR at an early time point of a treatment course.  
Finally, SPECT/CT imaging with 125I-labeled HVGGSSV peptide showed that TIP-1 
imaging can predict tumor cell response to ionizing radiation-induced cell death.  Thus, 
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this study suggested that TIP-1 imaging of radiation-inducible TIP-1 translocation onto 
the cell surface may predict tumor responsiveness to radiation in a time-efficient manner 
and thus tailor radiotherapy of cancer. 
 
Introduction 
 
Radiation therapy, in addition to surgery and chemotherapy, is one of the most commonly 
prescribed treatments for cancer patients. However, due to the heterogeneity of tumors, 
not all the tumors respond to a therapy regimen with a similar efficiency. Certain tumors 
respond to one treatment regimen better than others. The dose and delivery of treatments 
needs to be tailored to each individual patient and progression stage of the tumor (Kung 
et al., 2000). With current assessment approaches that mainly detect treatment-related 
anatomic or histological changes within the tumor (Dowsett and Dunbier, 2008), it 
usually takes weeks to months before therapeutic response can be detected and treatment 
efficacy can be determined. The long clinical delay before a response can be assessed 
costs patients valuable time on expensive and potentially ineffective treatments. A time 
efficient assessment is especially important in managing the highly malignant lung cancer. 
For this reason, identification of specific biomarkers for early assessment of cancer 
response can help personalized cancer therapy based on cancer responsiveness to a 
prescribed regimen. 
Targeting the tumor-specific biomarkers with imaging probes allows monitoring of tumor 
progression even before it is anatomically detectable. Proteomic and genomic approaches 
have been extensively explored to detect abundance of gene transcripts or products. 
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Identification of tumor-specific biomarkers with those approaches relies upon precise 
sampling and thus requires time- and labor-consuming validation. Compared to the 
proteomic or genomic techniques, phage display is economic, flexible and easily 
executed. In vivo phage display technology (Pasqualini and Ruoslahti, 1996) takes 
advantage of high fidelity without sampling bias and allows identifying circulation-
accessible markers that distinguish tumors from normal tissues by spatial location instead 
of expression abundance (Christian et al., 2003; Joyce et al., 2003; Zhang et al., 2005). 
Over the past decade, a myriad of phage display-derived peptides have been generated to 
bind to tumor cells and tumor-associated antigens (Joyce et al., 2003; Tenzer et al., 2004; 
Zurita et al., 2004). Although phage display derived peptides show promise in the in vivo 
tumor targeting and molecular imaging of cancer, due to a peptide’s small size and 
relatively low affinity to its molecular target, it is still a great challenge to identify the 
molecular targets that contribute to the peptide binding in vitro and in vivo. Lack of 
knowledge about the biological basis of peptide binding within tumors poses limitations 
on further development of the tumor-binding peptides for clinical applications. 
In a previous study, we have identified a small peptide (HVGGSSV) that specifically 
binds to tumors responding positively to ionizing radiation and tyrosine kinase inhibitors 
by using in vivo phage display (Han et al., 2008). Here, we report that Tax interacting 
protein 1 (TIP-1, also known as Tax1 binding protein 3, Tax1BP3) is a molecular target 
of the HVGGSSV peptide, and the radiation-inducible translocation of the predominantly 
intracellular TIP-1 protein onto the plasma membrane surface serves as a biomarker for 
tumor responsiveness to ionizing radiation. 
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Materials and Methods 
 
Cell culture 
Lewis Lung Carcinoma (LLC) and H460 lung carcinoma cells were obtained from 
American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained in 
DMEM medium with 10% fetal calf serum and 1% penicillin/streptomycin (Thermo 
Scientific Inc., Waltham, MA). Primary human umbilical vein endothelial cell (HUVEC) 
were obtained from Lonza Biologics (Riverside, CA) and maintained in EGM endothelial 
cell growth medium. Boyden chambers (Becton Dickinson Labware, Franklin Lakes, NJ) 
were used to prepare coculture of HUVEC and cancer cells. Constructs expressing 
shRNA sequences with green fluorescent protein (GFP) were purchased from Open 
Biosystems (Thermo Fisher Scientific, Huntsville, AL,USA), the TIP-1 specific shRNA 
(5’-GGCTAACAGCTGATCCCAA-3’) matches with TIP-1 mRNA transcripts, a non-
targeting sequence was used as a control. Transfection of the cells with recombinant 
plasmids was conducted with standard protocols (Felgner et al., 1987). Efficiency of the 
shRNA knocking down was detected by western blot analysis of whole cell lysates. Cells 
were irradiated with 300 kV X-rays using a Pantak Therapax DXT 300 Model Xray unit 
(Pantak, East Haven, CT). Antibodies and chemicals were purchased from Sigma (St. 
Louis, MO) unless otherwise stated. 
 
Phage Display 
Screening (Han et al., 2004b; Han et al., 2002) of a cDNA library displayed on T7 
bacteriophage was employed to identify proteins interacting with the HVGGSSV peptide. 
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In brief, the peptide-immobilized magnetic beads were prepared by incubation of 10 μl of 
2 mg/ml biotin-GCNHVGGSSV-COOH peptide (Genemed Synthesis Inc., San Antonio, 
TX) with 100 μl of streptavidin-coated Dynabeads (Invitrogen, Carlsbad, CA) at room 
temperature for 30 minutes. The same amount of a scramble peptide (Biotin-
GCSGVSGHGN-COOH) served as a control in all rounds of the screening. After 
removal of free peptides, the beads were resuspended in phosphate buffered saline (PBS, 
pH 7.2) containing 0.1% Tween 20 (PBST). The complex was incubated with 109 
plaque-forming units (pfu) of a T7Select human lung tumor cDNA library (Novagen, 
Gibbstown, NJ) in PBS. The mixture was incubated on a shaker for 2 hours at room 
temperature. The phage bound to the beads were magnetically separated from the 
unbound phage within solution. After washing 5 times with PBST, the phages recovered 
from the HVGGSSV peptide-coated beads were amplified in E.coli BLT5615 (Novagen) 
for subsequent rounds of screening. In each round of the screening, 107 pfu of the 
amplified phage were used. The phages recovered from both of the HVGGSSV peptide-
coated beads and control beads were also titrated; selectivity of the phage to the 
HVGGSSV peptide was estimated with ratio of the phage recovered from the target 
beads to those recovered from the control beads. The screening was repeated until 
significant (>1000) selectivity of the phage to the target beads was achieved. 
The phage recovered from the last round of the screening were cloned and amplified for 
enzyme-linked immunosorbent assay (ELISA)-based plate screening. Briefly, 96-well 
polystyrene plates (Corning Corp., Lowell, MA) were sequentially coated with 
streptavidin (0.2 μg/well), blocked with 2% BSA in PBS solution, and incubated with the 
biotinylated HVGGSSV or scrambled peptides (50 ng/well). 50 μl of the amplified phage 
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were added to each well for 2 hours incubation at room temperature. After the plates were 
washed five times with PBST, binding of the phage to peptides was detected with a rabbit 
antiserum against T7 phage (a kind gift from Dr. Toshiyuki Mori at National Cancer 
Institute, Frederick, MD) and secondary antibodies conjugated with horse radish 
peroxidase (HRP) (Sigma). Following PBST washing and incubation with 100 μl of 
substrate solution containing 2,2’-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt (ABTS, from Sigma) in 50 mM sodium citrate buffer, optical density 
was read at 405 nm. The insert sequences of the HVGGSSV-specific phage clones were 
amplified with polymerase chain reactions (PCR) by use of a forward primer (5’- 
GGAGCTGTCGTATCCAGTC-3’) and a reverse primer (5’-
TGGATTGACCGGAAGTAGAC-3’). The PCR products were purified for sequencing 
reaction by using a sequencing primer (5’-ATGCTCGGGGATCCGAATTC-3’). 
 
GST-TIP-1 protein production  
cDNA encoding TIP-1 was amplified using PCR by use of the selected phage clone as 
template. A construct encoding TIP-1 mutant with a dysfunctional PDZ domain (H90A) 
(Alewine et al., 2006) in pcDNA3.1 plasmid was a generous gift from Dr. Paul A. 
Welling at University of Maryland (Baltimore, MD). The DNA fragments encoding the 
functional TIP-1 and mutant TIP-1 were respectively subcloned into a pGEX-4T-1 vector 
(GE Healthcare) between BamH I and EcoR I sites to create fusion with glutathione S-
transferase (GST). The GST-fused proteins were expressed in E.coli XL-10 GOLD 
(Stratagene, Kirkland, WA) and purified by passing through a column packed with GST-
binding resin (Thermo Scientific Inc., Waltham, MA ) (Han et al., 2004a). The purified 
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proteins were dialyzed against PBS and quantified with Bradford methods (Bradford, 
1976). Size and purity of the proteins were examined by SDS-PAGE and coomassie blue 
staining. 
 
Peptide binding assay 
An ELISA was used to study the interaction of peptide with the recombinant TIP-1 
protein. All the biotinylated peptides were synthesized at Genemed Synthesis Inc. (San 
Antonio, TX), purity and molecular weight were assured with HPLC and mass 
spectrometry. Corning costar 96-well microtiter plates with high protein-binding capacity 
were coated with streptavidin (0.2 μg/well in PBS) overnight at 4°C. Plates were blocked 
with BSA and washed twice with PBST before incubating with the biotinylated peptides 
(50 ng/well) at room temperature for 1 hour. After washing with PBST, the purified GST-
TIP-1 or GST-TIP-1(H90A) proteins were added to each well (100 ng/well), respectively. 
The recombinant proteins bound to the immobilized peptides were detected by rabbit 
anti-GST antibody and a secondary antibody conjugated with HRP (Sigma). After 
washing with PBST as described above, ABTS solution was added to each well for color 
development, and optical density at 405 nm was read for quantification of peptide affinity 
to the recombinant proteins. 
 
Preparation of TIP-1 specific antibodies 
New Zealand white rabbits (Harlan Laboratories, Prattville, AL) were initially 
immunized with 100 μg of purified GST-TIP-1 protein premixed in a 1:1 ratio by weight 
with Titermax adjuvant (CytRx Corporation, Los Angeles, CA). One month after the 
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initial immunization, the animals were boosted with same amount of antigen twice with 2 
weeks interval without the adjuvant. Blood samples were periodically taken for antibody 
titration and specificity analyses by ELISA or western blot. When the anti-TIP-1 
antibody reached the designated high titer, the animals were sacrificed to collect the 
antiserum. The antiserum was purified by passage through protein A plus protein G 
columns (Sigma) to purify IgGs. TIP-1 specific antibodies were prepared from the 
purified IgGs by tandem absorption with bacterial proteins and the purified GST protein-
conjugated sepharose-4B (Sigma) to remove the IgGs that might bind proteins other than 
TIP-1. The final antibody was dialyzed against PBS and concentrated via Amicon 
centrifugal filters (Millipore, Billerica, MA). Specificity of the TIP-1 specific antibody 
was validated with whole cell staining and western blot analyses of whole cell lysates. 
All animal studies were conducted as approved by the Institutional Animal Care and Use 
Committee (IACUC) at Vanderbilt University. 
 
Antibody competition assays 
In vitro antibody competition experiments were performed using ELISA as described 
above in the peptide binding assay, except that the purified GST-TIP-1 proteins were pre-
mixed with serial diluted antibodies (starting at 10 μg/ml) before incubating with the 
immobilized peptides. In vivo antibody competition assays were conducted as described 
(Han et al., 2008). In brief, 1x106 LLC cells were implanted subcutaneously in both hind 
limbs of C57BL/6 Foxn1 null/null nude mice (4~5 weeks old, Harlan Laboratories). The 
tumors were allowed to grow to a size of 0.5 cm in diameter before treatment with X-ray 
radiation (5 Gy) on one tumor while the other tumor in the same mouse was used as an 
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untreated tumor control. All animals were anesthetized and shielded to only irradiate the 
tumors with 300 kV X-rays using a Pantak Therapax DXT 300 Model X-ray unit (Pantak, 
East Haven, CT). 200 μg of TIP-1 antibody or control antibody (normal rabbit IgGs) 
were injected through tail veins 4 hours after the radiation treatment, followed by 
injection of 100 μg of Alexa Fluor750 (Invitrogen)-labeled streptavidin that was 
complexed with the biotinlytated HVGGSSV peptides. Biodistribution of the peptide-
strepavidin complex within the tumor-bearing mice was monitored with In Vivo Imaging 
Systems 200 (IVIS 200) (Caliper Life Sciences, Hopkinton, MA) at the Vanderbilt 
University Institute of Imaging Sciences 24 hours after the peptide injection.  
 
Animal imaging 
Tumor model development, tumor treatment and Peptide or antibody labeling with Alexa 
Fluor 750 (Invitrogen) were conducted as described in previous publication (Han et al., 
2008). 20 μg of the fluorochrome-labeled antibody or peptide were intravenously 
administrated in each animal at 4 hours post irradiation. Optical images were taken at 24 
hours post the antibody injection with Xenogen IVIS-200 Optical In Vivo Imaging 
System (Calipers Life Sciences, Hopkinton, MA) at the Vanderbilt University Institute of 
Imaging Sciences. 
 
Flow Cytometry 
Lung cancer cells LLC and H460, HUVEC, or HUVEC co-cultured with either LLC or 
H460 (in a Boyden Chamber) were allowed to grow to 80% confluency, and irradiated 
with 0, 2, 4, 6 or 8 Gy. At variable time points after the treatment, the cells were detached 
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with accutase (eBioscience, San Diego, CA) and collected by centrifugation at 100x g for 
5 minutes. TIP-1 antibody in PBS with 2% BSA was added to the suspended cells and 
incubated on ice for 40 minutes. Free TIP-1 antibody was removed by centrifugation and 
resuspended in fresh PBS before Alexa Fluor 488-labeled goat anti-rabbit antibody 
(Invitrogen) was added and incubated for another 40 minutes on ice. Again the cells were 
washed and Annexin V-APC (BD Biosciences, Franklin Lakes, NJ) was incubated with 
the cells for 30 minutes on ice to detect apoptotic cells, Propidium Iodide (PI, BD 
Bioscience) was added in the last 10 minutes to detect cell plasma membrane integrity. 
Cells were scanned with a BD LSRII flow cytometer (BD Bioscience). 
TIP-1-positive and -negative H460 cells were sorted from PI-negative cell populations 
with FACSAria (BD Bioscience) for proliferation and radiosensitivity assays. Cell 
proliferation was surveyed with Ki-67 staining. Briefly, the sorted TIP-1 -positive or -
negative cells were cultured on glass coverslips at 37 oC for 24 hours. The cells were then 
fixed in 70% ethanol, permeated with 0.5% Triton X-100, and stained with Ki-67 
antibody (Vector laboratories, Burlingame, CA). Cells were counterstained with DAPI 
(4',6-diamidino-2-phenylindole) before examination under a fluorescence microscope. 
Susceptibility of the TIP-1-positive and –negative H460 cells was evaluated with a 
clonogenic assay in which the sorted cells were seeded and cultured with DMEM 
medium supplemented with 10% FCS and antibiotics in petri dishes for 4 hours before 
the cells were irradiated with X-ray at variable dosages. The colonies were allowed to 
form in 12 days. The colonies were stained with methylene blue solution and the colony 
numbers were counted for data analyses. 
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Statistical analyses 
All data were analyzed with the ANOVA to determine significance (with >95% 
confidence) of the differences. Results are presented as mean ± S.D. 
 
Results 
 
TIP-1 binds to the HVGGSSV peptide 
We have previously shown that one phage display-derived peptide HVGGSSV shows 
selective binding within a broad spectrum of tumors including lung cancers that had been 
treated with X-ray radiation and multiple tyrosine kinase inhibitors. The peptide binding 
within the treated tumors correlated to the overall efficacy of the treatment on tumor 
growth (Han et al., 2008). To further develop this peptide for molecular imaging and 
tumor-targeted drug delivery, we intended to identify the molecular target that enables 
the selective binding of the HVGGSSV peptide within irradiated tumors. Screening a T7 
phage-displayed human lung tumor cDNA library against the HVGGSSV peptide 
revealed TIP-1 as one protein that enables the selective binding of the HVGGSSV 
peptide within irradiated tumors. 
 
To identify the molecular target of the HVGGSSV peptide within irradiated tumors, a T7 
phage-displayed human lung tumor cDNA library composed of 107 independent phage 
clones was screened against the HVGGSSV peptide that was immobilized onto magnetic 
beads. The beads with a scrambled peptide were used as a control to deplete the non-
specific phage clones. The phage recovered from the HVGGSSV peptide-coated beads, 
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as well those recovered from the control beads, were titrated by following procedures as 
described (Han et al., 2004b; Han et al., 2002). After 5 rounds of such screening, it was 
found that total phage showed more than 1000-fold selectivity to the HVGGSSV peptide-
coated beads over the control beads (Fig. 6A), indicating the screening successfully 
enriched some phage clones that selectively bind to the HVGGSSV peptide. Single 
clones from the fifth round of the biopanning were isolated for further ELISA-based plate 
screening. Roughly 46.8% (22/47) of the analyzed phage clones exhibited specific 
binding to the HVGGSSV peptide but no detectable binding was observed to the control 
peptide which has same amino acid composition but with a scrambled amino acid 
sequence (data not shown). 17 out of the 20 (85%) sequenced HVGGSSV-binding phage 
clones encoded amino acid sequence of the TIP-1 (Rousset et al., 1998). Specificity of 
the TIP-1 expressing phage to HVGGSSV peptide was shown (Fig. 6B) in the ELISA-
based assays. 
 
TIP-1 binds to the HVGGSSV peptide via PDZ domain 
To further study the interaction of the HVGGSSV peptide and TIP-1 protein, gene 
fragments encoding TIP-1 protein were inserted into an expression plasmid to produce 
recombinant GST-TIP-1 proteins in E. coli. The GST tag was utilized to purify the 
recombinant proteins to homogeneity (Fig. 6D). Affinity of the HVGGSSV peptide with 
TIP-1 protein was studied with ELISA by use of the purified recombinant proteins and 
synthetic peptides (Fig. 6E). TIP-1 is a small protein of 124 amino acids, a PDZ-domain 
is the only functioning structure identified so far (Fig. 6C). The HVGGSSV peptide 
contains a canonical PDZ binding motif (-X-S/T-X-V/L/I, where X represents any  
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hydrophobic amino acids) (Kay and Kehoe, 2004), the peptide probably binds to TIP-1 
through the PDZ domain. Therefore a TIP-1 mutant protein (H90A) with abolished PDZ 
ligand binding capability (Alewine et al., 2006) was included in the binding assay. 
Several peptides with mutation within the PDZ binding motif were also included in the 
ELISA-based affinity study. The data showed that the HVGGSSV peptide binds to the 
TIP-1 protein through the PDZ domain, it can not bind to the H90A mutant which 
contains a dysfunctional PDZ domain. The scrambled peptide, as well as other peptides 
with single mutations within the PDZ binding motif, did not show significant binding to 
the TIP-1 protein (Fig. 6E). 
 
TIP-1 specific antibody competes with HVGGSSV peptide for TIP-1 binding 
TIP-1 antibody was developed by immunizing rabbits with the purified GST-TIP-1 
proteins. Specificity and reactivity of the TIP-1 antibody were determined by western 
Figure 6. HVGGSSV peptide binds to PDZ domain of the TIP-1 protein. A: 
Enrichment of phage with selective binding to the HVGGSSV peptide. Phages recovered 
from the five rounds of screening and those from the original phage library were subjected 
to selectivity analysis on beads coated with the HVGGSSV peptide or a scrambled peptide 
control, respectively. Shown are number (PFU) of phage recovered from the beads after the 
free phage were washed off. 109 PFU of phages were used in this assay. B: Specificity of 
the TIP-1-expressing phage to the HVGGSSV peptide. C: Diagram of TIP-1 protein shows 
location of PDZ domain and the critical amino acid (H90) for PDZ ligand binding; D: SDS-
PAGE image shows purity of the recombinant TIP-1 proteins and a dysfunctional mutant 
TIP-1 (H90A). The fusion proteins (~37 kD) were analyzed along with molecular weight 
markers. E: Relative association of the purified recombinant proteins to the synthetic 
peptides was evaluated with ELISA. In these assays, 100 ng of the purified GST/TIP-1 or 
GST/TIP-1(H90A) proteins were used per well, all the synthetic peptides were used as 50 
ng per well. The mutations in the PDZ binding motif were underlined. Shown are 
representative data from triplicate experiments. * p<0.05, n = 3, the Student's t-test. 
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blot analysis of whole LLC cell lysate and immunofluorescent staining of LLC cells in 
which TIP-1 expression had been depleted with specific shRNA. The TIP-1 specific 
antibody only recognized a single band corresponding to the endogenous TIP-1 protein 
(~14 kD) in a western blot analysis of the LLC whole cell lysates, with minor or 
undetectable binding to other unrelated proteins (Fig. 7A). Cell staining further 
demonstrated specificity of the TIP-1 antibody. We identified one out of a panel of 
shRNA constructs that efficiently down-regulated TIP-1 expression within LLC cells, as 
shown by western blot analysis of whole cell lysate (upper panel of Fig. 7B). This TIP-1 
targeting shRNA was selected for transfection of LLC cells and the transfection was 
tracked with GFP expression from the shRNA plasmid. Overlapping of the TIP-1 
antibody (red) and GFP (green) was observed within the LLC cells that were transfected 
with a construct with a control shRNA (pointed with arrow heads). The TIP-1 specific 
antibody did not stain the LLC cells that were transfected with a construct with the TIP-
1-targeting shRNA (pointed with arrows), because the target of the antibody had been 
depleted with the TIP-1 targeting shRNA (lower panel of Fig. 7B). These data 
demonstrated that the TIP-1 antibody did not bind to any protein other than TIP-1 within 
the cancer cells. These results confirm that this is a TIP-1 specific antibody. 
The TIP-1 specific antibody inhibits the HVGGSSV peptide binding to the recombinant 
TIP-1 protein in a dose-dependent manner as measured by ELISA (Fig. 7C), whereas the 
control antibody did not interfere with the binding. The results of these experiments 
demonstrate that the TIP-1 specific antibody share or overlap with the HVGGSSV 
peptide for common interacting areas within the TIP-1 protein. Therefore, this TIP-1 
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antibody was used to study the contribution of TIP-1 to the selective binding of the 
HVGGSSV peptide within irradiated tumors. 
 
TIP-1 mediates binding of the HVGGSSV peptide within irradiated tumors 
To determine if TIP-1 binds to the HVGGSSV peptide within irradiated tumors, 
antibodies were intravenously administrated in LLC tumor-bearing mice prior to the 
injection of the fluorophore-labeled HVGGSSV peptide. Optical imaging data showed 
that binding of the HVGGSSV peptide within the irradiated tumors was not affected by 
pre-injection of the control IgGs. However, pre-injection of the TIP-1 specific IgGs 
dramatically attenuated the accumulation of the fluorophore-labeled peptide within the 
irradiated tumors (Fig. 7D). These data clearly demonstrated that, at least in part, TIP-1 
mediates the selective binding of the HVGGSSV peptide within the irradiated tumors. 
 
TIP-1 specific antibody exhibited similar binding patterns as the HVGGSSV 
peptide within irradiated tumors 
We have previously shown that HVGGSSV peptide specifically binds to the tumors 
responding positively to radiation and/or tyrosine kinase inhibitors (Han et al., 2008). If 
TIP-1 contributes to the peptide accumulation within irradiated tumors, one logic 
prediction is that the TIP-1 antibody can recapitulate the biodistribution pattern of the 
HVGGSSV peptide in tumor-bearing mice. To test this hypothesis, nude mice bearing 
H460 or LLC xenografts were irradiated, Alexa Fluor-750 labeled TIP-1 antibody was 
injected via tail veins 4 hours after the radiation treatment by following the same protocol 
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that was used to study the biodistribution of the HVGGSSV peptide within tumor-bearing 
mice (Han et al., 2008). Optical images acquired 24 hours after the antibody injection 
indicated that the TIP-1 antibody had high selectivity to the irradiated tumors, but not the 
untreated tumors or normal tissues in both of the LLC and H460 tumor models (Fig. 8A). 
In this regard, accumulation of the TIP-1 specific antibody within the irradiated tumors 
was confirmed with immunohistochemical staining (Fig. 8B) of the retrieved tumor 
tissues after animal imaging. 
Radiation induces TIP-1 translocation onto the plasma membrane surface 
TIP-1 is a basically intracellular protein that is ubiquitously expressed within multiple 
Figure 7. TIP-1 specific antibody blocked the HVGGSSV peptide binding within 
irradiated tumors. A: Specificity of the TIP-1 antibody as revealed with western blot 
analysis of whole LLC cell lysate. The endogenous TIP-1 protein (~14 kD) recognized by 
the antibody is identified with an arrow. B: Specificity of the TIP-1 antibody as 
demonstrated in immunofluorescent staining of LLC cells that were transfected with 
shRNA plasmids. Effect of the TIP-1 targeting shRNA on TIP-1 expression was 
determined with western blot analysis (upper panel). In the cell staining, the transfected 
cells were tracked with GFP protein expression from the shRNA plasmids. TIP-1 was 
stained as red with the TIP-1 antibody. Cell nuclei were stained with DAPI. The LLC cells 
transfected with the control shRNA that did not affect TIP-1 expression are shown with 
arrow head, while the cells transfected with TIP-1 targeting shRNA that abolished TIP-1 
expression are identified with arrows (lower panel). C: ELISA-based in vitro competition 
assay. Serially diluted antibodies were pre-incubated with the purified GST/TIP-1 proteins 
(100 ng/well) before the complex was added to the plates coated with the HVGGSSV 
peptide (50 ng/well). The GST/TIP-1 protein associated to the immobilized HVGGSSV 
peptide was detected with GST-specific antibody. D: Optical images of LLC tumor-
bearing mice that were co-administrated with the Alexa Fluor 750-labeled HVGGSSV 
peptide and antibodies. LLC tumors in the left hind limbs were irradiated at 5 Gy 
(indicated with arrows). 200 µg of the TIP-1 antibody, or the control antibody, was 
injected at 2 hours post the IR treatment, followed by injection of Alexa Fluor 750-labeled 
HVGGSSV peptide at 4 hours post the IR treatment. Optical images were acquired 24 
hours after the peptide injection. The presented data represent three independent 
experiments. 
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Figure 8. TIP-1 specific antibody selectively homed to the irradiated tumors. A: NIR 
images of the TIP-1 antibody distribution within tumor-bearing mice. H460 and LLC 
tumors were developed in hind limbs of nude mice, respectively. Tumors are indicated 
within the dashed circles. The irradiated tumors (at 5 Gy) are indicated by arrows. Alexa 
Fluor 750-labeled control or TIP-1 specific antibodies were injected 4 hours after the 
irradiation. The representative optical images shown were acquired 24 hours after the 
antibody injection. B: Immunohistochemical staining of the intravenously administrated 
antibodies within the irradiated tumors. The imaged tumors were retrieved for detection of 
the antibodies within the tumors. The antibodies (rabbit IgGs) were detected with HRP-
conjugates and visualized with DAB (shown as brown). Hematoxylin (blue) was used for 
counterstaining. Representative images from H460 tumor sections are presented, high 
magnification (x400) images are shown as inserts. 
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organs (Kanamori et al., 2003). The tumor-specific and radiation-inducible binding of the 
HVGGSSV peptide and the TIP-1 antibody within tumor-bearing mice suggested that 
TIP-1 accessibility to the circulating peptide or antibody is inducible upon radiation 
treatment and limited within tumor cells. We used cultured LLC, H460 lung cancer cells 
and HUVEC cells to study the IR-induced TIP-1 translocation onto the cell surface. 
Western blot analysis of the whole cell lysates did not show dramatic changes in the TIP-
1 protein level after IR in all the three tested cells (data not showed). However, flow 
cytometric analysis showed that the percentage of the H460 cells with TIP-1 expression 
on the cell surface was elevated from basal level (untreated cells) of 4.67% to 13.3% in 
24 hours after IR treatment (Fig. 9A). This observation was supported by 
immunofluorescent staining of the surface-located TIP-1 on the irradiated H460 cells (Fig. 
9B). It was found that the translocation of the TIP-1 protein onto the H460 cell plasma 
membrane surface sustained for a prolonged period of time after the irradiation (Fig. 9C). 
The effect of IR on TIP-1 translocation is dose-dependent (Fig. 9D), higher doses of IR 
were more effective at inducing the TIP-1 translocation onto the cell surface. A similar 
effect of radiation on the TIP-1 expression on the cell surface were also observed on the 
LLC cells, but not the HUVEC cells even then the endothelial cells had been co-cultured 
with LLC or H460 cancer cells (Fig. 9F). These data suggested that radiation induced 
translocation of the intracellular TIP-1 onto the plasma membrane might be limited to 
cancer cells. 
The TIP-1 positive and negative H460 cells were sorted for western blot analysis to 
determine whether they represent two independent subgroups of cells with different TIP-
1 protein level. The result showed that the total TIP-1 levels were similar in both of the  
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TIP-1 positive and negative cells (Fig. 9E). Combined with the observations that IR did 
not significantly change overall TIP-1 protein levels in the tested cells, we concluded that 
radiation does not alter total protein levels of TIP-1 but rather appears to promote the 
TIP-1 translocation onto the plasma membrane surface. 
 
The radiation-induced TIP-1 translocation relates to reduced colony formation and 
proliferation potential and increased susceptibility to subsequent radiation 
treatment 
Annexin V profiling (apoptosis) and PI staining (membrane integrity and cell death) are 
commonly used to detect cellular response to cytotoxic treatment. H460 cells were 
Figure 9. Radiation induced TIP-1 translocation onto the plasma membrane of the 
cancer cells. A: Flow cytometric profile of TIP-1 expression on the H460 cell surface. TIP-
1 on the cell surface was detected with the TIP-1 antibody 24 hours after radiation 
treatment, a control IgG was included to demonstrate the antibody specificity. B: 
Fluorescent staining of the TIP-1 expression (green) on the cell surface of the irradiated 
H460 cells. DAPI was used for counterstaining. C: Time course study. The H460 cells were 
irradiated at 5 Gy and then fixed at variable time points after irradiation for flow cytometric 
analysis of the TIP-1 expression on the cell surface. Percentage of the TIP-1 positive cells 
was presented. D: The dose-dependence study. The H460 cells were irradiated with 
variable dose of X-ray, the cells were fixed 24 hours post the irradiation for profiling the 
TIP-1 expression on the cell surface with flow cytometry. Fold change of the TIP-1 positive 
cells was calculated by comparison to the untreated cells (counted as 1). E: Western blot 
analysis of TIP-1 expression within the TIP-1 positive or negative cells that were sorted 
from the irradiated (5 Gy) H460 cells 24 hours after the irradiation. Relative TIP-1 protein 
level was normalized to that of the actin control (counted as 1) and shown under the image. 
F: Flow cytometric profile of TIP-1 expression on the cell surface of LLC, H460 or 
HUVEC cells. The cells were treated with 5 Gy of X-ray, TIP-1 on the cell surface was 
profiled 24 hours post the radiation treatment. Fold change of the TIP-1 positive cells was 
calculated by comparison to the untreated cells (counted as 1). * p<0.01, n = 3, the 
ANOVA, each was compared to the untreated control, respectively. 
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irradiated (5 Gy) and dissociated 24 hours after the irradiation for flow cytometric 
analysis. Triple color flow cytometric profiling showed that the majority of cells with 
TIP-1 expressed on the cell surface (TIP-1 positive cells) are negative for both the dead 
cell marker (PI) and the apoptotic cell marker (Annexin V) (Fig. 10A). Among the total 
apoptotic cells (0.48%+1.41% = 1.89%), only one third (0.48% out of 1.89%) of them 
were TIP-1 positive. Among the TIP-1 positive cells (13.5%+0.48% = 13.98%), the 
majority (13.5% out of 13.98%) were Annexin V negative. Among all the dead cells 
(0.98%+6.19% = 7.17%), only a small portion (0.98% out of 7.17%) of the dead cells 
were stained as TIP-1 positive. Among all the TIP-1 positive cells (13%+0.98% = 
13.98%), the majority (13% out of 13.98%) were PI-negative. These data suggest that 
radiation-inducible TIP-1 translocation onto the cell surface does not overlap with 
treatment associated apoptosis or cell death. 
The TIP-1 positive and negative H460 cells were sorted from the irradiated H460 cells 
for in vitro colony formation, proliferation and radiation susceptibility studies. Although 
both irradiated TIP-1 positive and negative cells showed very low capability to form 
visible colonies on petri dishes, a statistically significant difference was observed 
between the two subgroups of cells with respect to the capability of colony formation 
(Fig. 10B). Ki-67 staining (Fig. 10C) further showed that fewer TIP-1-positive cells were  
undergoing proliferation than the TIP-1-negative cells. Clonogenic assays (Fig. 10D) 
indicated that fewer TIP-1 -positive cells survived after subsequent radiation treatment 
than the TIP-1 -negative cells. All these data suggested that the radiation-inducible TIP-1 
translocation onto the cancer cell surface serves as a biomarker for identifying radiation-
responding cancers before the onset of apoptosis and cell death. 
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Figure 10. TIP-1 translocation onto the cell surface is a biomarker distince from 
those for cell death and apoptosis. A: Flow cytometric profile of TIP-1 expression 
on the cell surface, apoptosis (Annexin V) and cell death or membrane integrity (PI) at 
24 hours after the radiation (5 Gy) treatment of the H460 cells. Percentage of the cells 
in each section was shown in the representative profile images from three independent 
experiments. B: Colony formation on petri dishes of the TIP-1 positive and negative 
cells sorted from the irradiated H460 cells. The H460 cells were irradiated at 5 Gy. 
The TIP-1 positive and negative cells were sorted 24 hours post the radiation 
treatment. Colony formation capability of the two subgroups of cells was shown as 
colony number per 1000 seeded cells. C: Proliferation capability of the sorted cells as 
determined with Ki-67 staining. Percentage of the proliferative cells among the 
counted cells was shown. D: Susceptibility of the sorted H460 cells to subsequent 
irradiation. Shown are data from clonogenic assays. Survival fractions are presented to 
show the difference of the radiation susceptibility between the TIP-1 positive and 
negative cells. * p<0.05, n = 3, the Student's t-test. 
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Discussion 
 
Not all tumors, not even within the same classifications, respond to a treatment in the 
same way. Personalized or tailored treatment of tumor calls for efficient and reliable 
assessment of tumor responsiveness. Even though anatomic and functional imaging have 
been extensively investigated and applied to assess tumor response to treatment, new 
biomarkers with sound biological relevance are still needed to assess tumor response to 
treatment in a time-efficient manner. 
 
In an effort to identify such biomarkers, we previously identified a short peptide 
(HVGGSSV) using in vivo phage display technology. The peptide demonstrated potential 
in assessing the tumor responsiveness to radiation and tyrosine kinase inhibitors at an 
early stage of treatment courses (Han et al., 2008). As demonstrated within multiple 
heterotopic and orthotopic tumor models, the peptide selectively binds to the responding 
tumors, and the peptide accumulation within the treated tumors correlates to the overall 
biological effects of the treatment on the tumor growth control. In this study, TIP-1 was 
identified as one molecular target of the HVGGSSV peptide. TIP-1 specific antibody 
competed with the HVGGSSV peptide for binding within irradiated tumors, and 
exhibited similar binding patterns as the peptide in tumor-bearing mice. It was further 
identified that radiation induced translocation of the basically intracellular TIP-1 protein 
onto the cell surface occurred in a dose-dependent manner. The treatment-induced TIP-1 
expression on the cell surface is detectable in the first few hours after the treatment and 
before the onset of treatment associated apoptosis or cell death. In fact, the majority of 
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the cells expressing TIP-1 on the cell surface are the live but still responding cancer cells, 
albeit such cells are less potent in proliferation and more susceptible to subsequent 
radiation treatment. Although it still under investigation to understand the mechanism and 
biological consequence of the radiation-induced TIP-1 translocation, these data support 
one conclusion that the radiation-inducible translocation of TIP-1 onto the cell surface 
holds promise as one surrogate biomarker in assessing the tumor responsiveness to 
ionizing radiation. 
 
Discovery of the TIP-1 translocation onto the cell surface as one biomarker of tumor 
response to radiation took advantage of phage display technologies. Firstly, a peptide 
HVGGSSV was identified with selective binding to the tumors responding to IR and 
tyrosine kinase inhibitors by in vivo phage display (Han et al., 2008). Cancer cells 
distinguish themselves from normal cells by expressing proteins or receptor on the cell 
surface, imaging of such surface proteins such as EGFR has been studied to track the 
tumor progression or even monitor tumor response to treatment (Manning et al., 2008). 
We envision that the treatment-inducible protein expression on the cancer cell surface 
holds promise as a surrogate biomarker for imaging-based assessment of the tumor 
responsiveness to treatment. Compared to genomic and proteomic profiling (Han et al., 
2006) that focus on the gene structure and overall expression abundance, in vivo phage 
display prefers the molecules that are localized on the cell surface and circulation 
accessible. Moreover, unlike the subcellular proteomic profiling (Oh et al., 2004) that has 
been explored in biomarker discovery in vivo, the in vivo phage display takes advantage 
of minimal sample bias and the real time in vivo binding within the sophisticated tissues 
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and cell structures. Secondly, TIP-1 was identified as the molecular target of the 
HVGGSSV peptide through biopanning a phage-displayed cDNA library. In an effort to 
identify the molecular target(s) of the HVGGSSV peptide, no meaningful data was 
generated through BLAST search for homologous sequences (Zurita et al., 2004), affinity 
purification accompanied with mass spectrometric identification (Christian et al., 2003), 
or yeast-two hybrid screening of cDNA libraries (Zhang et al., 2005). Low affinity or low 
abundance of the corresponding molecular target(s) might contribute to the difficulty in 
identification of the molecular target(s) of the short peptide. A phage-displayed cDNA 
library was screened against the HVGGSSSV peptide, rounds of biological amplification 
and affinity selection significantly enriched the peptide-binding clones that lead to the 
TIP-1 identification. This study further demonstrated the potential of screening phage-
displayed cDNA library for the discovery of molecular targets of peptides with simple 
structure and low affinity. 
 
TIP-1 is ubiquitously expressed within multiple organs (Besser et al., 2007). It is 
predominantly localized in the cytoplasma (Besser et al., 2007; Reynaud et al., 2000), 
with rare or undetectable expression in the nucleus or on the cell plasma membrane under 
normal culturing condition. It has been studied as a PDZ antagonist in modulating cell 
proliferation, polarity, migration and stress response (Alewine et al., 2006; Hampson et 
al., 2004; Kanamori et al., 2003; Reynaud et al., 2000). However, its biological functions 
in cancer biology and cell stress response are still under investigation. Our flow 
cytometry and cell imaging data showed that the TIP-1 translocation onto the cell surface 
after X-ray irradiation was dominantly observed in cancer cells, but did not extend to 
 53
endothelial cells as tested in this study by the use of HUVEC (Fig. 9F). This difference is 
not related to the abundance of the TIP-1 protein within the cells. Western blot analysis 
of TIP-1 expression within the whole cell lysates indicated that TIP-1 was expressed in 
all the cell lines including the HUVEC with comparable protein level (data not shown). 
Tissue staining also showed that the intravenously administrated TIP-1 antibody was 
dominantly associated to the tumors cells (Fig. 8B). These data suggested that the 
radiation-induced TIP-1 translocation onto the cell surface might be limited to the tumor 
cells. This conclusion is also supported by our previous observations that the HVGGSSV 
peptide did not bind to normal tissues that had been irradiated or inflamed with LPS and 
TNF-α (Han et al., 2008). Conversely, radiation-induced translocation of other 
intracellular proteins such as P-Selectin (Hallahan et al., 1998) and intercellular adhesion 
molecule-1 (ICAM-1) (Hallahan et al., 1996) are reportedly associated with inflammatory 
response to ionizing radiation and thus not specific to tumor response to the radiation 
treatment. In this regard, the radiation-induced TIP-1 translocation onto the cancer cell 
surface is a unique biomarker of tumor response to radiation. 
 
Although further investigation is needed to elucidate the mechanism(s) by which X-ray 
irradiation induces the TIP-1 translocation onto the cell surface and the biological 
relevance of the TIP-1 translocation in the tumor response to radiation, we revealed that 
the cells responding to radiation by relocating TIP-1 onto the cell surface are live but 
have reduced capability to proliferate and form colonies. The cells with TIP-1 expression 
on the cell surface are more susceptible to subsequent radiation treatment, compared to 
the counterparts of the cells without TIP-1 expression on the cell surface. These data 
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partially explain why TIP-1 imaging with the HVGGSSV peptide is predictive in 
assessing the tumor responsiveness to radiation (Han et al., 2008). The TIP-1 
translocation was detectable in the first few hours after radiation treatment and before the 
onset of the treatment associated apoptosis and cell death, suggesting a potential 
mechanism to assess tumor response to IR at an early time point of a treatment course. 
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CHAPTER III 
 
MIGRATION AND INVASION OF HUMAN GLIOMAS IS CONTROLLED BY 
TIP-1-MEDIATED SPATIAL AND TEMPORAL REGULATION OF RHO 
GTPASE ACTIVATION 
 
Abstract 
 
Unlike other PDZ domain containing proteins that usually are composed of multiple 
structural and functional domains, Tax interacting protein (TIP-1) is unique in that almost 
the entire protein forms a single PDZ domain. Therefore, TIP-1 is predicted to play 
different roles from the classic PDZ proteins. In this study, we report a positive 
correlation between TIP-1 expression and human glioma malignancy based on tissue 
array analysis. The correlation between TIP-1 expression and glioma progression was 
further supported by mouse model studies using orthotopic glioma xenografts in which 
down-regulation of TIP-1 with shRNA was found to increase animal survival 
significantly. Upon histological examination of tumor tissues, we found that TIP-1 
knockdown inhibited tumor invasion into normal brain tissues, which was confirmed by 
in vitro glioma cells migration and invasion assays. Downregulation of TIP-1 also caused 
cellular morphology changes, with more membrane ‘spike’ protrusions and fewer 
matured lamellipodia, as well as slower reorientation of the microtubule-organizing 
center (MTOC). Using recently released protein structures, we discovered that TIP-1 
interacts with beta-PIX and rhotekin with high affinity through the PDZ domain. These 
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two proteins are GEF/Effectors for Rho GTPases. Knockdown of TIP-1 significantly 
increased the interactions of beta-PIX and rhotekin with a PDZ scaffold protein, scribble, 
that plays critical roles in directional cell migration. Consequently, TIP-1 deficiency 
resulted in mislocalization of rhotekin and beta-PIX within the migrating cells. The 
mislocalization of rhotekin and beta-PIX lead to abnormal activation of RhoA and 
Rac1/Cdc42 in the TIP-1 knockdown cells. Taken together, our study indicates that TIP-1 
is required for malignant glioma invasion. It revealed that TIP-1 controls cells migration 
and invasion through regulating the intracellular localization of beta-PIX and rhotekin 
and the activation of RhoA, Rac1 and Cdc42. Furthermore, TIP-1 regulation provides a 
novel mechanism of coordinately regulating Rho GTPases activities. 
 
Introduction 
 
The ability of cancer cells to invade surrounding normal tissues requires a series of early 
events, including the formation of membrane protrusions in response to chemotactic 
signals, extension of membrane protrusions at the leading edge and retraction of the cell 
body at the trailing edge. This coordinated reorganization of cell cytoskeleton is primarily 
driven by the Rho GTPases (Jaffe and Hall, 2005). Rho GTPases act as molecular 
switches, cycling between a GTP-bound active form and GDP-bound inactive form. The 
activation of Rho GTPases is mediated by guanine-nucleotide exchange factors (GEFs). 
Once activated, Rho GTPases bind to and regulate a spectrum of functionally diverse 
downstream effectors, initiating a network of cytoplasmic and nuclear signaling cascades. 
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The spatially and temporally orchestrated regulation of Rho GTPases functions is critical 
for cell migration (Machacek et al., 2009; Pertz et al., 2006). 
 
Rho GTPases have been reported to contribute to most steps of cancer initiation and 
progression (Gomez del Pulgar et al., 2005). Several Rho GTPases are upregulated in 
some human tumors, including gliomas (Benitah et al., 2004; Hwang et al., 2004; Oellers 
et al., 2009; Zavarella et al., 2009; Zhai et al., 2006). Malignant gliomas are highly 
aggressive cancers, clinical treatment of these tumors is challenging due to extensive 
infiltration of individual tumor cells into adjacent brain tissue. These invading cells 
render these cancers resistant to current treatments of surgical removal in combination 
with radiation, chemo- and immuno-therapies. 
 
In our previous studies, we discovered that a small PDZ protein TIP-1 (also known as 
Tax1bp3) can be used as a biomarker for early evaluation of radiotherapy efficacy (Han 
et al., 2008; Wang et al., 2010), and TIP-1 expression protected glioma cells from 
radiation treatment (Han M, unpublished). In contrast to other PDZ proteins which 
usually contain multiple functioning domains and serve as scaffold proteins to assemble 
big structural or signaling complexes, almost the entire TIP-1 protein (124 amino acids) 
forms a single PDZ domain (~98 amino acids). The unique structure suggests TIP-1’s 
different functions from the classic PDZ proteins. Until now, the molecular function of 
TIP-1 has remained elusive. TIP-1 is mainly a cytosolic protein,  although it is also found 
to associate with the plasma membrane and be inside the nucleus (Kanamori et al., 2003; 
Olalla et al., 2008).  TIP-1 is expressed in almost all tissues. Soon after its discovery, 
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TIP-1 was identified to interact with rhotekin, a Rho GTPase - RhoA effector protein. 
This interaction is involved in Rho signaling to the serum response element (Reynaud et 
al., 2000). TIP-1 also interacts with glutaminase L in mammalian brain. However the 
exact mechanisms by which TIP-1 regulates glutaminase L function is not yet elucidated 
(Aledo et al., 2001; Olalla et al., 2001; Olalla et al., 2008). In colon cancers, TIP-1 was 
found to bind to beta-catenin and inhibit beta-catenin transcriptional activity (Kanamori 
et al., 2003). The interaction between TIP-1 and potassium channel Kir2.3 blocks Kir2.3 
membrane localization and affects cell polarity (Alewine et al., 2006). TIP-1 can also 
interact with NMDA receptor, which is thought to play a critical role in synaptic 
plasticity. Knockdown of TIP-1 increased the neurotoxicity of NMDA on neuron cells 
(Cui et al., 2007). In another study using a zebrafish model, TIP-1 expression level was 
found highest in the central nervous system of the zebrafish embryo, and TIP-1 can 
induce filopodia growth and is important for gastrulation movements during zebrafish 
development (Besser et al., 2007). TIP-1 was also the target of several virus oncoproteins, 
such as the Tax protein of the human T-lymphotropic virus Type I (Rousset et al., 1998), 
human papillomavirus E6 protein (Hampson et al., 2004) and avian influenza NS1 
protein (Obenauer et al., 2006). Although the biological functions were not determined in 
these studies, the diversity of all these interacting proteins indicates that TIP-1 protein has 
a broad effect in living cells. Recently, the crystal structure of TIP-1 was resolved. 
Besides the classic PDZ motif binding pocket, a second binding site was identified to 
assist PDZ binding (Yan et al., 2009; Zhang et al., 2008). 
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In this study, we report that high levels of TIP-1 expression correlated with human 
glioma progression, and TIP-1 down-regulation inhibited glioma cell migration and 
invasion in vitro and in a mouse model of intracranially implanted human glioma 
xenograft. We demonstrat that  TIP-1 controls cells migration and invasion through 
regulating the intracellular localization of beta-PIX and rhotekin and the activation of 
RhoA, Rac1 and Cdc42. 
 
Materials and Methods 
 
Cell Culture and Stable shRNA Transfection 
Human glioblastoma cancer cells lines D54 and T98G were obtained from Dr. Yancie 
Gillespie (University of Alabama-Birmingham, Birmingham, AL), and purchased from 
ATCC (Manassa, VA), respectively. Both lines were maintained in DMEM/F12 media 
(Invitrogen, Carlsbad, CA), and stably transfected with shRNAs (Sigma-Aldrich, 
TRCN0000159034 and TRCN0000162886, St Louis, MO) using Lipofectamine 2000 
according to the manufacturer's instructions (Invitrogen). Positive clones were selected 
with puromycin (Sigma-Aldrich). Tip-1 downregulation was assessed by Western blot as 
described previously(Wang et al., 2010).  
 
Antibodies and Reagents 
TIP-1 polyclonal antibody from rabbit was produced in our lab as described before 
(Wang et al., 2010). Beta-PIX antibody (SH3 domain) was obtained from Millipore 
(Billerica, MA). Antibodies against Rac1, beta-catenin, GM130 and paxillin were 
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purchased from BD Biosciences (Rockville, MD). Anti-Pericentrin, Ki67 and RhoA 
antibodies were obtained from Abcam (Cambridge, MA). Anti-Flag (M2), beta-Actin 
antibodies were purchased from Sigma. Anti-Scrib (H300), Cdc42, Rhotekin antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 594 
labelled Phallotoxins and all other Alexa Fluor dye labeled secondary antibodies were 
obtained from Invitrogen. 
 
Plasmids Constructs 
A construct encoding cMyc tagged TIP-1 mutant with a dysfunctional PDZ domain 
(H90A) (13) in pcDNA3.1 plasmid was a generous gift from Dr. Paul A. Welling at 
University of Maryland(Baltimore, MD). The plasmid expressing flag-tagged beta-PIX 
(Mayhew et al., 2006) was obtained from Addgene (Cambridge, MA). To create a c-
terminal PDZ binding motif mutation (from -WLQSPV to -ALQAPV) of beta-PIX, we 
used the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, Santa Cruz, CA) with 
primers 5’-atatgaacgaccctgccgcggatgaggccaatctatagctcgag-3’, and 5’-
ctcgagctatagattggcctcatccgcggcagggtcgttcatat-3’. 
 
Migration and Invasion Assays 
Cell migration and invasion assays were performed using 8-µm porous Boyden chambers 
(Corning Life Science, Lowell, MA) coated with or without Matrigel (BD Biosciences) 
according to the manufacturer’s recommendations. Cell migration was also assayed using 
the wound healing assay (Etienne-Manneville, 2006). 
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Cell Staining and Imaging 
The cells were fixed and permeabilized in 4% formaldehyde solution and stained with 
corresponding antibodies. For study of migrating cells at the wound edge, cells were 
allowed to grow to confluence on cover slips. After starving the cells overnight with 
serum free media, the cell monolayers were scratched with a 200ul pipette tip, and 
allowed to grow in fresh media for the indicated time before fixation for staining. The 
images were acquired using a Zeiss LSM 510 inverted confocal microscope. To quantify 
the percentage of individual proteins located at the cell leading edge, the fluorescent 
intensity of each protein was measured using Image J software (NIH). At least 50 cells 
were included in each measurement. 
 
In vivo Xenograft Tumor Model of Glioma 
To access the impact of TIP-1 on glioma progression, an orthotopic mouse brain tumor 
model was used. The intracranial tumor model was described previously (Geng et al., 
2006). Briefly, D54 cells or D54 cells with TIP-1 knockdown (n=2x104) in 20uL of PBS 
were injected 3mm deep (from the skull surface) into the right burr hole of nude mice. 
The mice were monitored daily for hypomotility, absence of grooming behavior, and 
weight loss. All the animal work was conducted as approved by the Institutional Animal 
Care and Use Committee (IACUC). A Kaplan-Meier survival curve was used to graph 
these surrogate behaviors for survival. Statistical analysis was performed using Log Rank 
Test. 
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Immunohistochemistry of Tumor Tissues 
To study histologic changes in intracranial tumor model, tumors were retrieved after 
survival assays, and fixed in formaldehyde and embedded in paraffin. 6µm thick tumor 
sections were deparaffinized in graded alcohols, rehydrated and heated in 10mM citrate 
buffer (pH 6.0) for antigen retrieval using a pressure cooker. The tissue slides were 
subsequently stained with Ki67 antibody or TIP-1 antibody and counterstained with 
hematoxylin. 
For the study of human glioma tissues, tissue microarrays with pathological diagnosis of 
astrocytoma, glioblastoma, glioblastoma multiforme (GBM) and normal tissue were 
purchased from US Biomax (Rockville, MD). The tissue slides were processed as 
described above for TIP-1 staining and counterstained with hematoxylin. TIP-1 
expression intensity was scored on a four point scale as either negative (1), weak (2), 
moderate (3), or strong (4). Mean expression scores multiplied by percent of the positive 
cells in the field (Quick's combined score system) are presented for normal brain, grade I, 
grade II, grade III and grade IV gliomas, respectively, in a graphic format using error bars 
with 95% confidence intervals (CI). Differences among these groups were compared 
using ANOVA. A p-value of ≤0.05 was considered statistically significant. 
 
Rho GTPases Activation Assay 
Rho GTPases activation was determined by using either RhoA Activation Assay Kit or 
Rac1/Cdc42 Activation Assay Kit (Cell Biolabs, San Diego, CA). Briefly, the cells were 
lysed in lysis buffer and centrifuged at 13,000g for 10min. The supernatant was mix with 
either rhotekin RBD-agarose beads (for activated RhoA) or PAK1 PBD-agarose beads 
 63
(for activated Rac1/Cdc42) for 1 hour at 4°C. The activated Rho GTPases were analyzed 
by Western immunoblot. 
 
Results 
 
High expression levels of TIP-1 correlate with glioma malignancy 
A correlation between TIP-1 expression and clinical presentation of the malignant 
gliomas was recently revealed with reanalysis of microarray data (Han M, unpublished). 
In this study, we used a TIP-1 specific antibody (Wang et al., 2010) to profile TIP-1 
expression and intracellular location within arrayed human brain tumor tissues that 
contain pathologically verified tissue samples from patients with progressive 
glioblastomas of different malignancy. Immunohistochemistry staining indicated that 
TIP-1 is mainly a cytosolic protein, with some localized to the plasma membrane (Fig. 
11A). Semi-quantitative analysis of TIP-1 expression revealed a positive correlation 
between the expression level of TIP-1 and the malignancy of glioblastoma (Fig. 11B). 
The normalized mean TIP-1 expressions in the malignant glioma were much higher than 
those in normal brain tissues. TIP-1 level was elevated with the increased malignancy of 
glioma (Fig. 11B), except in grade IV gliomas which have the similar TIP-1 level as 
grade III glioma, and there were little or no expression of TIP-1 in normal brain tissues. 
 
Downregulation of TIP-1 in glioma cells extended survival of mice with 
intracranially implanted tumors 
To further investigate the positive correlation between high levels of TIP-1 expression  
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Figure 11. TIP-1 expression correlates with human gliomas malignancy. (A) TIP-1 
expression in human gliomas. Representative tissue cores of a tissue microarray stained 
with a monospecific anti-TIP-1 polyclonal antibody demonstrate weak staining in normal 
brain and lower grade gliomas (panels a and b), but strong staining in higher grade gliomas 
(panels c and d). Higher magnification images revealed TIP-1 location in the cytosol (panel 
e) and on the plasma membrane (panel f). (B) Semi-quantitative histological evaluation of 
TIP-1 expression within human glioma tissue blocks. TIP-1 expression intensity was scored 
on a four point scale as either negative (1), weak (2), moderate (3), or strong (4). Mean 
expression scores multiplied by percentage of the positive cells in the field (Quick's 
combined score system) are presented for normal brain, grade I, grade II, grade III and 
grade IV gliomas, respectively, in a graphic format using error bars with 95% confidence 
intervals (CI). Statistically significant differences were noted between normal brain and 
gliomas of different malignant grades. *, p < 0.001 and between different grades gliomas; 
#, p < 0.005 (ANOVA). Case numbers for each group of tissues were marked under the bar 
graph. 
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and malignancy of glioma, we examined the impact of TIP-1 down-regulation on glioma 
progression using an orthotopic brain tumor model. D54 was selected as a malignant 
human glioma cell line for this study since mRNA sequencing and western blot analyses 
indicated that D54 cells express high level of wild-type TIP-1 protein (Fig. 17B and 
unpublished data). D54 cells with TIP-1 stably knockdown (Fig. 13A) and control cells 
were implanted intracranially into mice brains. Extent of survival was analyzed by the 
Kaplan-Meier method. In contrast to the control groups in which all mice died in 28 days, 
a significant increase in the survival time (about 8 more days) was observed in the TIP-1 
Knockdown group (Fig 12B). 
 
Downregulation of TIP-1 inhibited glioma cell migration and invasion 
To elucidate the roles of TIP-1 in glioma progression, we first studied the impact of TIP-
1 on cell proliferation. Both in vitro (Fig 12A) and in vivo (Fig 12D) experiments 
indicated that knockdown of TIP-1 did not change glioma cell proliferation rate. At the 
end of the survival experiments, the tumors were resected from mice brains. 
Immunohistochemical studies with TIP-1 antibody staining confirmed that TIP-1 
expression was still silenced in the knockdown tumors. One significant difference 
between control and TIP-1 knockdown tumors was that, in contrast to the extensive 
invasion of tumors formed with regular D54 cells or those transfected with a control 
shRNA, TIP-1 downregulation dramatically reduced invasion of the D54 tumor cells into 
surrounding normal brain tissues (Fig 12C). Therefore, these results revealed a potential 
role of TIP-1 in regulating cell migration and invasion. 
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TIP-1-regulated cancer cell migration and invasion were further studied with two human 
glioma cell lines, D54 and T98G, which have distinct invasive capability. TIP-1 
expression was stably knocked down using RNA interference approach. Two 
independent targeting sequences were designed to minimize the off-target effects. TIP-1 
specific shRNA expression resulted in >90% inhibition of endogenous TIP-1 compared 
with control cells (Fig.13A). In the Boyden chamber migration assay, knockdown of TIP-
1 resulted in a significant inhibition of cell migration in both cell lines (Fig. 13B). 
Similarly, but to a greater extent, cell invasion was inhibited in both cell lines with TIP-1 
downregulation in the Boyden chamber-based invasion assays (Fig. 13C). Consistent 
with these results, cell motility study using the wound healing assay also revealed a 
similar decrease in the motility of the TIP-1 silenced cells compared with the control cells 
(Fig. 13D). The control cells closed the wound gaps much faster than TIP-1 knockdown 
cells as surveyed in 12hrs after the wound scratch. 
Figure 12. Downregulation of TIP-1 inhibited glioma progression in mice. (A) TIP-1 
expression was stably knocked down in the human malignant glioma cell line D54 using an 
shRNA construct. The in vitro cell proliferation rates were measured by counting cell 
numbers every 24hrs for 3 days. (B) Same numbers of control D54 cells, D54 cell 
transfected with non-targeting or TIP-1 specific shRNA sequences were implanted 
intracranially in Athymic nude Foxn1nu mice. The mouse survival time was monitored, and 
the survival data was analyzed by Kaplan Meier method (* p<0.0002). (C) At the end of the 
survival studies, tumors were recovered from the mice brains. The brain tumor tissues were 
stained with TIP-1 antibody (brown color) to confirm the efficiency of TIP-1 knockdown. 
Infiltration of the tumor cells into the surrounding normal brain tissues was visualized with 
hematoxylin staining. (D) In vivo tumor cell proliferation rates were determined by Ki67 
staining of the brain tumor tissues. Data are expressed as mean±SD. Scale bar: 50um.  
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TIP-1 regulated the MTOC orientation during the directional migration 
One hallmark of the directional migration is the reorienting of the microtubule-organizing 
center (MTOC) and the repositioning of  the Golgi apparatus toward the leading edge at 
the early stages of the cell migration (Kupfer et al., 1982; Ueda et al., 1997). To 
understand the mechanisms by which TIP-1 regulates cancer cell migration and invasion, 
we investigated MTOC reorientation in the control and TIP-1 knockdown T98G glioma 
cells. In the wound-healing assays, scratching the cell monolayer induces cell 
reorientation and migration in a direction perpendicular to the wound. The correctly 
reoriented cells will have the centrosome facing toward the scratch edge. Results from the 
assays revealed that TIP-1 depletion significantly perturbed scratch-induced MTOC 
reorientation (Fig. 13E). There were fewer cells with the correctly orientated centrosome 
after knockdown of TIP-1. 
TIP-1 interacts with Rho GTPases GEF/effectors - beta-PIX and rhotekin  
Directional migration of cells and cytoskeleton reorganization are regulated by multiple 
signaling pathways including the spatially and temporally orchestrated activation and 
inactivation of Rho GTPases. To explore the molecular mechanisms by which TIP-1 
regulates cell migration and invasion, we studied TIP-1 interacting proteins. So far, there 
are about eleven TIP-1 interacting proteins published, with the majority identified 
through the yeast two hybrid method (Hampson et al., 2004; Kanamori et al., 2003; 
Reynaud et al., 2000; Rousset et al., 1998; Yan et al., 2009). These proteins belong to 
different protein families, such as oncoproteins, ion channels, cytoskeleton proteins, etc. 
The complexity of TIP-1 targeting proteins made it difficult to understand its functions.  
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Recently, the structure of TIP-1 was resolved with X-ray crystallography and nuclear 
magnetic resonance spectroscopy (NMR). Besides the classic type I PDZ binding motif, a 
tryptophan residue at the -5 position to the c-terminus was identified as critical for TIP-1 
specific binding (Durney et al., 2009; Yan et al., 2009; Zhang et al., 2008). With this 
information, we searched a PDZ protein database (Beuming et al., 2005) and discovered 
three proteins that have this binding motif (Table 1). Of these three proteins, beta-PIX has 
not previously been described as interacting with TIP-1. Beta-Pix is a guanine nucleotide 
exchange factor (GEF) for Rho GTPases Rac1 and Cdc42, and it is involved in regulating 
actin cytoskeleton reorganization and cell migration (Campa et al., 2006; Feng et al., 
Figure 13. Depletion of TIP-1 restrained glioma cell migration and invasion. (A) 
Western blot showing TIP-1 expression in two glioma cell lines (D54 and T98G) with 
stably expressing TIP-1 shRNAs or control shRNA, respectively. (B) Migration of D54 
and T98G with or without TIP-1 knocking down were studied using Boyden chamber 
assay as described in Materials and Methods. Bar graph represents the number of 
migrated cells at 12hrs after seeding the cells on the top of the membrane. Results shown 
are mean ± SD of 3 independent experiments (*, p<0.01). Representative images showed 
the migrated cells across the membrane. Cell nuclei were stained with DAPI (blue). (C) 
Invasion of D54 and T98G with or without TIP-1 knock down were studied using 
Boyden chamber assay. The bar graph represents the number of invaded cells at 16hrs 
after seeding the cells on the top of the membrane. Results shown are mean±SD of 3 
independent experiments (*p<0.01). Representative images showed the invaded cells on 
the membrane. Cell nuclei were stained with DAPI (blue). Scale bar: 150um. (D) Tumor 
cell migration analyzed by the wound healing assay. T98G monolayer cells were 
scratched and monitored for 12hrs to study TIP-1 functions in migration. (E) MTOC 
reorientation assay. Seven hours after scratch wounding, T98G cells were fixed and 
stained with anti-pericentrin (centrosome, green) and GM130 antibodies (Golgi, red) and 
DAPI (nucleus, blue). The bar graph represents percentage of wound-edge cells having 
their MTOC facing toward the scratch orientation. Results shown are mean ± SD of 3-5 
independent experiments with at least 500 cells being scored (*p<0.01). 
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2010; Nayal et al., 2006; Za et al., 2006). Another protein, rhotekin, is an effector protein 
that can only bind to GTP bound active form of RhoA (Reid et al., 1996). A couple of 
studies indicated that rhotekin plays a role in cytoskeleton and focal adhesion 
reorganization (Ito et al., 2005; Nagata et al., 2009). The third protein, beta-catenin, also 
interacts with actin cytoskeleton through alpha-catenin. Therefore, all three TIP-1 
interacting proteins further suggested the potential functions of TIP-1 in cytoskeleton 
reorganization. 
Because Rho GTPases are directly involved in regulating MTOC reorientation and cell 
migration and invasion (Osmani et al., 2006), we focused on the interactions of TIP-1 
with beta-PIX and rhotekin in this study. In immunoprecipitation assays, all three 
proteins were pulled down with TIP-1 wild type proteins, but not with the TIP-1 mutant 
with a dysfunctional PDZ domain (Fig. 14A), confirming the published data showing that 
TIP-1 interaction with beta-catenin and rhotekin is mediated by the PDZ domain  
(Kanamori et al., 2003; Reynaud et al., 2000). We further show that TIP-1 binds to beta-
PIX at the c-terminal PDZ binding motif, and that mutation within the PDZ binding motif 
of beta-PIX from -WLQSPV to -ALQAPV abolished its interaction with TIP-1 (Fig. 
14B). Inside the migrating T98G cells, TIP-1 was located at the trailing edge, in the cell 
body, and it was also found associated with the plasma membrane at the leading edge 
(Figs.14C, D). TIP-1 was found colocalized with beta-PIX at the leading edge and in the 
cell body (Fig. 14D). On the other hand, rhotekin was spotted mainly in the cell body and 
trailing edge, and it was colocalized with TIP-1 at these two intracellular locations (Figs. 
14C, D). 
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Figure 14. TIP-1 interacts with beta-PIX and rhotekin. (A) Western blot results of 
immnuoprecipitation of cMyc-TIP-1 in the cells transfected with either cMyc tagged 
TIP-1 wild type or a mutant with a dysfunctional PDZ domain. Beta-catenin, rhotekin 
and beta-PIX were blotted with specific antibody, respectively. (B) 
Immunoprecipitation of cMyc-TIP-1 in cells co-transfected with cMyc-TIP-1 (wild 
type) and flag-beta-PIX (wild type) or a flag-beta-PIX mutant with mutations in the c-
terminal PDZ binding motif. (C) Immunofluorescent staining of T98G cells with TIP-1 
antibody (green) and Rhotekin antibody (red). Arrows indicate the colocalization of 
both proteins. (D) Immunofluorescent staining of T98G cells with TIP-1 antibody (red) 
and beta-PIX antibody (green). Arrows indicate the colocalization of both proteins. 
Scale bars: (C and D) 50um. 
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TIP-1 affects the interaction between beta-PIX and rhotekin with PDZ scaffold 
proteins  
The PDZ binding motif on beta-PIX and rhotekin is used to associate these proteins to 
PDZ scaffold proteins (Audebert et al., 2004; Ito et al., 2006). Scribble is a PDZ scaffold 
proteins that guides the establishment of cell polarity in various organisms. It has been 
reported that scribble can interact with beta-PIX or beta-catenin and locate them to 
certain parts of the cell (Audebert et al., 2004; Osmani et al., 2006; Sun et al., 2009). 
Therefore, we used scribble as the referral protein to study how TIP-1 regulates the 
protein interactions and intracellular localization of beta-PIX and rhotekin. 
The results from Western blot of total cell lysates showed that depletion of TIP-1 protein 
did not change the level of either beta-PIX or rhotekin in T98G cells (Fig.15A), 
Wnt pathway; bind to alpha-
catenin and actin cytoskeleton
-WFDTDLBeta-catenin
GEF for Rac1/Cdc42-WLQSPVBeta-PIX
RhoA effector-WDETNLRhotekin
FunctionsPDZ binding 
motif*
Protein
Table 1: TIP-1 interacting proteins
* Letters in Bold indicate the specific TIP-1 recognition motif 
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suggesting TIP-1 did not directly regulate the stability or expression of these proteins. To 
investigate the impact of TIP-1 on the location of these proteins, we first studied the 
interaction between beta-PIX, rhotekin and scribble. In a wound scratch-induced cell 
migration assay, scribble was pulled down with anti-Scrib antibody from cell lysates 
before and after the scratch wound. Besides beta-PIX, rhotekin was also shown to bind to 
scribble, the first time such an interaction has been reported. The bar graph shows the 
densitometry quantification of the results (Fig.15B). In the control cells, the scratch 
wound induced twice as much beta-PIX and rhotekin binding to scribble protein. 
Interestingly, in TIP-1 depleted cells, the basal level of the scribble interaction was 
increased for both beta-PIX and rhotekin. However, compared with the more than 2 fold 
increase of rhotekin binding to scribble, beta-PIX interaction with scribble did not change 
after the scratch wound (Fig. 15B). The changes in the interactions were also confirmed 
by immunofluorescent staining of glioma cells after a scratch wound. An increased 
leading edge localization of beta-PIX and rhotekin was found associated with TIP-1 
depletion (Fig.15D). In contrast to the equal distribution at the leading edge in control 
cells, beta-PIX was only discretely located at tips of the leading edge of TIP-1 
knockdown cells (Fig. 15C). The cells also showed a highly branched morphology 
compared with the control cells (Figs. 15C, D, 18A,B). As for rhotekin, it was mainly 
located in the cell body and trailing edge in the control cells, but associated with leading 
edge (~2 folds increase) after knocking down TIP-1 (Fig.15D). Therefore, the robust 
changes in protein interactions and intracellular localization of beta-PIX and rhotekin 
indicated that TIP-1 controlled cell migration through regulating the intracellular location 
of two effector/GEFs of Rho GTPases. 
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TIP-1 regulated Rho GTPases location and activation 
Rho GTPases regulate the cytoskeleton rearrangement. The effectors/GEFs decide the 
location and activation of Rho GTPases. Because TIP-1 interacts with two effector/GEFs, 
we decided to investigate TIP-1’s impact on Rho GTPase location and activation. In the 
control cells with high level expression of TIP-1, scratching on the cell monolayer 
induced a robust activation of Rac1 (2 fold increase), and to a lesser extent activation of 
Cdc42. RhoA activity did not show significant change. While in TIP-1 depleted cells, 
Rac1 and Cdc42 activities were slightly decreased after wounding. However, RhoA 
activity showed a robust increase (>2 fold) (Fig. 16A). Similar to the location change of 
beta-PIX and rhotekin, more Rac1 and Cdc42 were associated with cell leading edge. 
They were located to the tips of branched membrane structure in TIP-1 depleted cells, 
and colocalized with beta-PIX at these spots (Fig. 16B, C). Significantly more RhoA 
protein was found concentrated at spots at the leading edge where rhotekin was binding 
(Fig.16D). The active RhoA can stimulate stress fiber formation (Nobes and Hall, 1995; 
Ridley and Hall, 1992). Consistent with the increased activity of RhoA, there were more 
cells (~80%) forming stress fibers in TIP-1 depleted cells (Fig. 16E). Also, without the 
continuous distribution of Rac1 and Cdc42 at the leading edge, there were no actin fibers 
formed along the leading edge (Fig.16E). 
 
Discussion 
 
TIP-1 is a unique PDZ domain containing protein in that almost the entire protein is a  
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PDZ domain. With no extra domains, TIP-1 supposedly can not carry out functions like  
classic PDZ proteins which serve as scaffolds to assemble large structures or signaling 
complexes. Instead, TIP-1 was considered to function  as an antagonist (Alewine et al., 
2006; Kanamori et al., 2003). In this study, we report a novel function of TIP-1 in 
progression of human malignant glioma and directional cell migration. Tissue array 
studies revealed a correlation between TIP-1 protein expression and human glioma 
malignancy. The positive correlation between TIP-1 expression and glioma progression 
was further supported by a survival study using murine orthotopic glioma xenograft 
models in which down-regulation of tumor TIP-1 significantly increased mouse survival.  
Histological examination of the resected tumor tissues indicated that TIP-1 depletion 
restrained tumor cell migration and invasion, that was further confirmed with in vitro  
 
Figure 15. TIP-1 affects the interactions of scribble with beta-PIX and rhotekin. (A) 
Western blot analysis of beta-catenin, beta-PIX and rhotekin protein levels within total 
cell lysates of control or TIP-1 depleted T98G glioma cells. (B) Cells were lysed at the 
indicated time after scratch wounding. Immunoprecipitations with anti-Scrib or irrelevant 
(Ctrl Ab) antibodies were performed and analyzed by western blot with the antibodies 
against beta-pix, rhotekin and scribble, respectively. Blots shown are representative of 
three independent experiments. The bar graph is the densitometry quantification of the 
blot results. (* p<0.001) (C) 4hrs after scratch wounding, cells were fixed and co-stained 
with both beta-PIX antibody (green) and Scribble antibody (red) to study their location 
inside the cells. (Scale bar: 50um) (D) 4hrs after wounding, cells were fixed and co-
stained with both rhotekin antibody (red) and Scribble antibody (green). (Scale bar: 
50um). The percentages of each protein located at the leading edge were quantified by 
measuring fluorescence intersity and results were shown in the bar graph. (* p<0.05, 
ANOVA) 
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migration and invasion assays. Therefore, our results support the potential utility of TIP-1 
as a molecular marker and therapeutic target of malignant glioma. 
Interestingly, TIP-1 level did not show any further increase in the two highest grades of 
gliomas (grade III vs. grade IV glioma) (Fig.11B), which indicates a threshold TIP-1 
protein level associated with tumor malignancy. These results were consistent with 
previous studies showing ectopic expression of TIP-1 reduced the proliferation and 
anchorage-independent growth of colorectal cancer cells (Kanamori et al., 2003).  
The highly conserved amino acid sequence across species (Fig.17) suggests essential 
biological roles of TIP-1 in molecular and cellular processes. However, with only one 
simple but very common PDZ domain and a variety of interacting proteins, it is 
challenging to understand how TIP-1 regulates migration and invasion of glioma cells. 
Recently, the crystal structure of TIP-1 was resolved and it provided us some insight into 
the structural requirement for a highly selective protein association between TIP-1 and 
Figure 16. TIP-1 regulates subcellular localization and activation of Rho GTPases. 
(A) Monolayer of T98G cells stably transfected with control shRNA or TIP-1 shRNAs 
were lysed 0 min or 30 min after wounding. Lysates were incubated with agarose beads 
coupled to PAK1-PBD peptide or Rhotekin-RBD peptide to pull down the active 
Rac1/Cdc42 or RhoA, respectively. The affinity precipitated active Rac1/Cdc42/RhoA 
and total Rac1/Cdc42/RhoA were analyzed with western blotting. Results are 
representative of 3 independent experiments. Bar graph is the densitometry quantification 
of the blot results. (* p<0.02) (B) 4hrs after wounding, cells were fixed and co-stained 
with both beta-PIX antibody (green) and Rac1 antibody (red)  to study their subcellular 
localization within the T98G cells. Arrows indicate the colocalization of both proteins. 
(Scale bar: 50um) The cells were also stained to colocalize beta-PIX (green) and Cdc42 
(red) (C), rhotekin (red), RhoA (green) (D). The fluorescent intensities of each protein 
were measured, and the percentages of individual proteins located at the leading edge 
were calculated. (*p<0.002, ANOVA). (E) Staining of actin (red) with phalloitoxins to 
visualize stress fiber formation.  (Scale bar: 50um). The percentages of cells with strong 
stress fiber staining were quantified. (*p<0.001, ANOVA) 
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the its interacting partners (Yan et al., 2009; Zhang et al., 2008). From the protein 
complex structure, a tryptophan residue at the -5 position to the C-terminus of PDZ 
binding motif was found critical for the TIP-1 specific binding. With this information, we 
searched a PDZ protein database and discovered two new proteins (beta-PIX and rhotekin) 
containing this binding motif. The specific interactions were confirmed by 
immunoprecipitation assays and colocalization of these proteins at leading or trailing 
edges of the migrating glioma cells. Both proteins belong to a family of guanine 
nucleotide exchange factor (GEF) / effector for Rho GTPases, with beta-PIX associating 
with active Rac1/Cdc42 and rhotekin binding to active RhoA. Among all Rho GTPases, 
Rac1, Cdc42 and RhoA are the three most studied in cytoskeleton reorganization and cell 
migration. Rac1 induces the formation of lamellipodia and membrane ruffles, Cdc42 
induces the formation of filapodia, and RhoA triggers actin stress fiber formation and the 
retraction of the cell body (Amano et al., 1997; Hall, 1998; Kimura et al., 1996). 
Considering TIP-1 knockdown caused cell morphological changes with more membrane 
‘spikes’ (Figs.15C & 18A,B), we postulated that TIP-1 regulates the cell motility through 
those Rho GTPases. 
 
It is generally accepted that temporally and spatially regulated GTPase activation is 
required for the proper initiation of downstream signaling events including protrusion at 
the leading edge and rear retraction of cell body, although the molecular mechanisms that 
control these temporally and spatially activation of Rho GTPases are not 
comprehensively understood yet (Pertz et al., 2006; ten Klooster et al., 2006). In recent 
years, accumulating evidences indicate that Rho-GEF/Effectors can locate and direct the  
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Homo        1 MSYIPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
Canis       1 MSYIPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
Rattus      1 MSYIPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
Mus         1 MSYTPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
Bos         1 MSYVPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
Gallus      1 MSYVPGQPVTAVVQRIEIHKLRQGDNLILGFSIGGGIDQDPTQNPFSEDKTDKGIYVTRV 
Danio       1 MSFIPGQPVTAVVQRIEILKLRDGDNLILGFSIGGGIDQDPSQNPFSEDKADKGIYVTRV 
tXenopus    1 MSYIPGQPVTAVVQRVEIYKLHQGDNLILGFSIGGGIDQDPAQNPFSEDKTDKGIYVTRV 
lXenopus    1 MSFIPGQPVTAVVQRVEIHKLHQGENLILGFSIGGGIDQDPAQNPFSEDKTDKGIYVTRV 
 
 
Homo       61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
Canis      61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
Rattus     61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
Mus        61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
Bos        61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
Gallus     61 TEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRNEEVVRLLVTRQSLQKAVQQ 
Danio      61 SEGGPAEVAGLRVGDKIMQVNGWDMTMVTHDQARKRLTKKKEDVVRLLISRKSLEEVVRQ 
tXenopus   61 TEGGPAEVAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKKNEEVVRLLVTRKSLQEAVRQ 
lXenopus   61 TEGGPAEVAGLQMGDKIMQVNGWDMTMVTHDQARKRLTKKNEEVVRLLVTRKSLQEAVRQ 
 
 
Homo      120 SMLS- 124 
Canis     120 SMLS- 124 
Rattus    120 SMLS- 124 
Mus       120 SMLS- 124 
Bos       120 SMLS- 124 
Gallus    120 SMMS- 124 
Danio     120 SMMQR 125 
tXenopus  120 SMRP- 124 
lXenopus  120 SMRP- 124 
 
A
B Human_TIP-1    1 MSYIPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
T98G_TIP-1     1 MSYIPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
D54_TIP-1      1 MSYIPGQPVTAVVQRVEIHKLRQGENLILGFSIGGGIDQDPSQNPFSEDKTDKGIYVTRV 
 
 
Human_TIP-1   61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
T98G_TIP-1    61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
D54_TIP-1     61 SEGGPAEIAGLQIGDKIMQVNGWDMTMVTHDQARKRLTKRSEEVVRLLVTRQSLQKAVQQ 
 
 
Human_TIP-1  121 SMLS 
T98G_TIP-1   121 SMLS 
D54_TIP-1    121 SMLS 
 
Figure 17. (A) Multiple sequence alignment of TIP-1 protein across several species, 
and (B) TIP-1 Sequences in glioma cell lines D54 and T98G 
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Figure 18. (A) Cell morphology change after TIP-1 knockdown in T98G cells. 
Red: Actin; Green: TIP-1, (B) Highly Branched Structure formed in TIP-1 
knockdown T98G cells, with beta-PIX located at the tips of branches. Green: 
beta-PIX. 
A
B
Actin TIP-1
Ctrl shRNA TIP-1 shRNA1 TIP-1 shRNA2
Beta-PIX
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Rho GTPases signal output through their interaction with scaffold proteins (Garcia-Mata 
and Burridge, 2007; Jaffe and Hall, 2005; Marinissen and Gutkind, 2005). Scribble is a 
PDZ scaffold protein that is required for establishing epithelial polarity and limiting cell 
proliferation (Bilder et al., 2000). It has been reported that scribble works as a scaffold 
protein by interacting with beta-PIX through the PDZ domain, which controls the 
localization of activated Cdc42 and Rac1 to the leading edge (Audebert et al., 2004; 
Osmani et al., 2006; ten Klooster et al., 2006). However, almost nothing is known about 
roles of rhotekin in these molecular events. 
  
Using scribble as a referral protein, we investigated the impact of TIP-1 on the 
temporally and spatially regulated location of the Rho GEF/effectors and activation of 
RhoA, Rac1 and Cdc42. The results showed that TIP-1 knockdown significantly 
increased the basal level of scribble protein interaction with beta-PIX and rhotekin. 
However, after scratch wounding, only the association between rhotekin and scribble was 
significantly increased. Beta-PIX did not show any increased interaction with scribble 
after wounding (Fig. 15B). In addition to changes in levels of interaction, the locations of 
beta-PIX and rhotekin inside the cells were also dramatically changed. The results 
illustrated that PDZ binding motifs are important for proper localization of GEF/Effectors, 
and indicated that TIP-1 can regulate the selective interaction and subcellular localization 
of beta-PIX and rhotekin inside the migrating cells. Regarding the differential binding 
pattern between beta-PIX and rhotekin, we speculate that the high concentration of 
rhotekin in glioma cells might give it some advantages to compete with beta-PIX for 
scribble binding (Figs.15A,B). Although we can not rule out the possibilities that 
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rhotekin interacts with scribble with a higher affinity, more studies are needed to further 
elucidate the detailed mechanisms governing these differential protein interactions. 
Within the TIP-1 knockdown glioma cells, the changes in the associations of beta-PIX 
and rhotekin with membrane associated scaffold proteins provide the basis for the 
irregular activation of Rac1, Cdc42 or RhoA. Consistent with this, more RhoA was 
located to the leading edge especially to the spots where rhotekin is localized, and it was 
strongly activated after wounding. On the other hand, there was barely any change of the 
level of Rac1/Cdc42 associated with the leading edge, except that their distribution 
patterns were dramatically altered, and their activities were decreased. It is also 
interesting to notice that the activity decrease of Rac1 is much greater than that of Cdc42, 
which is probably caused by the counteraction between RhoA and Rac1 (Yamaguchi et 
al., 2001). With the disorganized Rho GTPases activities after TIP-1 depletion, the cell 
did not form normal actin fiber structures along the lamellipodia at the leading edge, and 
MTOC reorientation was much delayed. There were more stress fibers formed, and cell 
motility was dramatically decreased. 
 
Taken together, we propose that TIP-1 orchestrates cell migration through directing beta-
PIX and rhotekin to the corresponding subcellular locations for temporally and spatially 
activation of Rho GTPases - RhoA, Rac1 and Cdc42.  However, the molecular 
mechanisms by which TIP-1 coordinately regulates the location of beta-PIX and rhotekin 
remain to be defined. Further studies on the potential posttranslational modifications of 
TIP-1 and roles in selective protein interactions are needed to elucidate the structural 
basis of the protein interactions required for temporal and spatial regulation of Rho 
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GTPases activation in cell migration. It is interesting to notice that the third TIP-1 
interacting protein, beta-catenin, also interacts with actin through alpha-catenin, and may 
help to stabilize the cytoskeleton. Therefore, further studies on the mechanisms by which 
TIP-1 regulates beta-catenin activities will provide more insights into TIP-1’s 
contributions to cell migration and malignancy of brain tumors. 
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CHAPTER IV 
 
GENERAL DISCUSSION AND FUTURE DIRECTION 
 
Peptide Receptor Identification 
Cancer targeted imaging has become an indispensable tool in modern diagnostics because 
it provides accurate and fast diagnosis of cancer. Peptides are small molecules with great 
target permeability, and they will not elicit an immune response (Ladner et al., 2004). 
Therefore, peptide-based imaging probes have been increasingly used in cancer targeted 
imaging. In our previous studies, we identified one peptide (-HVGGSSV) specifically 
binds to radiation treatment responsive tumors (Han et al., 2008). Several following 
studies already demonstrated that nanoparticles/vesicles conjugated with HVGGSSV 
peptide showed an increased tumor-specific delivery and bioavailability of drugs in 
tumors after radiation treatment (Hariri et al., 2010a; Hariri et al., 2010b). 
 
To understand the physiological impact that underlies peptide binding, we need to know 
the targets of the peptide. However, due to peptides small size and low binding force, it is 
a great challenge to identify peptides’ targeting proteins. In Chapter II of this thesis study, 
besides the traditional affinity purification methods, we explored several new techniques 
for isolating the target of HVGGSSV peptide. To increase binding affinity between the 
peptide and its receptor, we first conjugated a photoactive linker (4-(N-
Maleimido)benzophenone, Sigma) on the peptide, which can be activated by UV light 
and form a covalent bond between the peptide and its target protein. However, in both in 
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vivo and in vitro experiments, the proteins pulled down using this method were 
predominantly nonspecific binding proteins. It is probably because that the conjugated 
photoactive linker changed the surface hydrophobicity of the whole peptide molecules. 
With no better chemical linkers available, we turned to a different method – phage 
display. Different from the phage peptide library we used for isolating HVGGSSV 
peptide, a phage cDNA library was screened to identify the target protein of the peptide. 
After several rounds of screening, the target protein with specific interactions was 
dramatically enriched in the pool of phage eluted from the HVGGSSV peptide. And we 
identified TIP-1 as the target of HVGGSSV peptide. The specific interaction was 
confirmed by in vitro biochemical assays. Therefore, our results demonstrated the 
potentials of screening phage-displayed cDNA library in discovery of molecular targets 
of the peptides with simple structure and low affinity. 
 
TIP-1 Is A Biomarker For Assessment Of Tumor Response To Ionizing Radiation 
Treatment 
In Chapter II of this thesis research, we have demonstrated that TIP-1 protein mediated 
binding of the HVGGSSV peptide within irradiated tumors, and radiation could induce 
TIP-1 translocation onto the cell surface. Therefore, TIP-1 can be used as a biomarker for 
evaluation of tumor response to ionizing radiation. However, the mechanisms of TIP-1 
translocation onto the cell surface and the physiological impact of this translocation are 
still not clear. Based on TIP-1 function analysis in Chapter III, we assume that the 
translocation could sequester TIP-1 from the cytosol and inhibit cell migration and 
invasion. Furthermore, the exposure of TIP-1 on the cell surface might also provide a 
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stimulatory signal to activate the immune system. But elucidation of the exact 
mechanisms and functions of the translocation requires further investigation. 
 
TIP-1 Can Serve As A Target For Radiation Guided Immunotherapy 
Monoclonal antibodies are the most widely used form of immunotherapy to treat cancer. 
Monoclonal antibodies can be used all by itself or attached with drug or toxins or 
radioactive substances to kill cancer cells (Lin et al., 2005). The studies from Chapter II 
have shown that TIP-1 specific antibody exhibited similar binding patterns as the 
HVGGSSV peptide within irradiated tumors. These results indicate that TIP-1 is 
available for antibody binding in vivo, and provided the basis for monoclonal antibodies 
production and further investigation of TIP-1 targeted radiation guided immunotherapy. 
 
Regulation of TIP-1 Protein Function 
Almost entire TIP-1 protein forms a single PDZ domain. This unique structure indicates 
that TIP-1 can not function as a scaffold protein like other PDZ proteins. Studies carried 
out in Chapter III of this thesis research revealed that TIP-1 interacted with beta-PIX and 
rhotekin through the PDZ domain, and regulated the spatial and temporal activation of 
RhoA, Rac1 and Cdc42. Although PDZ proteins have been reported to interact with Rho 
GEF/effectors and control Rho GEF/effectors targeting and activation, all of these PDZ 
proteins are membrane associated scaffold proteins that recruit Rho GEF/effectors to 
appropriate subcellular destinations (Audebert et al., 2004; Park et al., 2003; Penzes et al., 
2001). With our current knowledge, TIP-1 probably functions as an antagonizer to 
interfere with the binding of Rho GEF/effector to PDZ scaffold proteins. The 
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mechanisms by which TIP-1 coordinately regulate three major Rho GTPases need to be 
further investigated. It is probably cell type specific due to the different expression 
pattern of beta-PIX and rhotekin in different tissues. The phosphorylation site predicted 
from structure analysis is located inside the PDZ motif binding pocket on TIP-1 and may 
play an important role in regulating the dynamic interaction between TIP-1 and its 
binding proteins. Furthermore, dimmerizaton of TIP-1 or a second domain on TIP-1 are 
both possible mechanisms that regulate TIP-1 functions. Further investigation will 
provide us more insight into TIP-1 functions. 
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